nctId large_stringlengths 11 11 | briefTitle large_stringlengths 34 291 | officialTitle large_stringlengths 34 277 | acronym large_stringlengths 3 14 ⌀ | organization large_stringlengths 7 89 | overallStatus large_stringclasses 8
values | studyType large_stringclasses 2
values | phases large_stringclasses 9
values | enrollmentCount int64 0 10k | leadSponsor large_stringlengths 7 89 | sponsorClass large_stringclasses 4
values | collaborators large_stringlengths 2 271 | conditions large_stringlengths 12 342 | interventions large_stringlengths 2 149 | briefSummary large_stringlengths 82 3.57k | sex large_stringclasses 3
values | minimumAge large_stringclasses 18
values | maximumAge large_stringclasses 18
values | healthyVolunteers bool 2
classes | startDate large_stringlengths 7 10 ⌀ | completionDate large_stringlengths 7 10 ⌀ | primaryCompletionDate large_stringlengths 7 10 ⌀ | firstPostedDate large_stringdate 1999-11-04 00:00:00 2026-05-01 00:00:00 | lastUpdatePostedDate large_stringdate 2006-01-18 00:00:00 2026-05-13 00:00:00 | locations large_stringlengths 2 13.1k | hasResults bool 2
classes | url large_stringlengths 44 44 | scrapedAt large_stringlengths 24 24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT01213784 | Optimized Glycemic Control in Heart Failure Patients With DM2:"Effect on Left Ventricular Function and Skeletal Muscle" | Optimized Glycemic Control in Type 2 Diabetics With Heart Failure:"Effect on Left Ventricular Function and Skeletal Muscle" | HFDM | University of Aarhus | COMPLETED | INTERVENTIONAL | ["PHASE2"] | 40 | University of Aarhus | OTHER | ["The Danish Diabetes Association"] | ["Type 2 Diabetes", "Heart Failure"] | ["OTHER: all antidiabetic drugs will be appliable"] | The investigators wish to investigate wether a more strict diabetic control improves cardiac function, muscle strength, exercise capacity and decreases symptoms.
The investigators hypothesis is that improving the glycemic control in suboptimized diabetics with heart failure will improve cardiac performance, muscle str... | ALL | 18 Years | 90 Years | false | 2010-09 | 2012-11 | 2012-11 | 2010-10-04 | 2015-03-06 | [{"facility": "Dept. of cardiology, Aarhus university hospital Skejby", "city": "Aarhus", "state": "Central Jutland", "country": "Denmark"}] | false | https://clinicaltrials.gov/study/NCT01213784 | 2026-05-14T17:51:03.369Z |
NCT03060538 | A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease | A Phase Ib, Randomized, Blinded, Placebo-Controlled, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous BFKB8488A in Patients With Type 2 Diabetes Mellitus and Patients With Non-Alcoholic Fatty Liver Disease | null | Genentech, Inc. | COMPLETED | INTERVENTIONAL | ["PHASE1"] | 154 | Genentech, Inc. | INDUSTRY | [] | ["Diabetes Mellitus, Type 2", "Non-Alcoholic Fatty Liver Disease"] | ["DRUG: BFKB8488A", "OTHER: Placebo"] | This is a Phase Ib, randomized, blinded, placebo-controlled, multiple ascending-dose study of the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of BFKB8488A in participants with Type 2 diabetes mellitus (T2DM) and participants with non-alcoholic fatty liver disease(NAFLD). A maximum of ap... | ALL | 18 Years | 75 Years | false | 2017-03-05 | 2019-12-13 | 2019-12-13 | 2017-02-23 | 2020-03-27 | [{"facility": "Pinnacle Research Group Cullman", "city": "Anniston", "state": "Alabama", "country": "United States"}, {"facility": "Pinnacle Research Group; Llc, Central", "city": "Anniston", "state": "Alabama", "country": "United States"}, {"facility": "Southern California Research Center, Inc.", "city": "Coronado", "... | false | https://clinicaltrials.gov/study/NCT03060538 | 2026-05-14T17:51:03.463Z |
NCT02675855 | GrafixPRIME® for the Treatment of Chronic Diabetic Foot Ulcers | A Multicenter, Randomized, Single-Blind Study Comparing the Efficacy of GrafixPRIME® to Active Comparator for the Treatment of Chronic Diabetic Foot Ulcers | null | Osiris Therapeutics | COMPLETED | INTERVENTIONAL | ["PHASE4"] | 75 | Osiris Therapeutics | INDUSTRY | [] | ["Foot Ulcer, Diabetic"] | ["OTHER: GrafixPRIME®", "PROCEDURE: Dressing Application", "DEVICE: Off-loading (walking boot)"] | The objective of the study is to compare the efficacy of weekly GrafixPRIME® administration to an Active Comparator in patients with chronic DFUs in a randomized, single-blind study. | ALL | 18 Years | 80 Years | false | 2016-01 | 2017-07 | 2017-07 | 2016-02-05 | 2017-07-17 | [{"facility": null, "city": "Arizona City", "state": "Arizona", "country": "United States"}, {"facility": null, "city": "California City", "state": "California", "country": "United States"}, {"facility": null, "city": "New Mexico", "state": "New Mexico", "country": "United States"}] | false | https://clinicaltrials.gov/study/NCT02675855 | 2026-05-14T17:51:03.504Z |
NCT01185743 | Antipsychotics and Gene Expression in Soft Tissues | Effect of Atypical Antipsychotics on Gene Expression in Soft Tissues of Healthy Subjects - A Placebo Controlled Randomised Pilot Study | null | Medical University of Vienna | COMPLETED | INTERVENTIONAL | ["PHASE4"] | 16 | Medical University of Vienna | OTHER | [] | ["Schizophrenia", "Diabetes"] | ["DRUG: olanzapine", "DRUG: ziprasidone", "DRUG: placebo"] | Schizophrenia is a severe chronic and disabling mental disorder and is associated with a significant reduction in life expectancy. Atypical antipsychotic treatment compliance may be jeopardized because of drug induced weight gain and abnormalities in carbohydrate and lipid metabolism.
Aim: to gain data on drug related... | MALE | 18 Years | 45 Years | true | 2010-07 | 2017-01-01 | 2017-01-01 | 2010-08-20 | 2017-03-23 | [{"facility": "Medical University of Vienna", "city": "Vienna", "state": "State of Vienna", "country": "Austria"}] | false | https://clinicaltrials.gov/study/NCT01185743 | 2026-05-14T17:51:03.591Z |
NCT01827735 | Regulatory T Cells in Type 1 Diabetes Patients Treated With IL-2 | Adaptive Study of IL-2 Dose on Regulatory T Cells in Type 1 Diabetes (DILT1D) | DILT1D | Cambridge University Hospitals NHS Foundation Trust | COMPLETED | INTERVENTIONAL | ["PHASE1", "PHASE2"] | 40 | Cambridge University Hospitals NHS Foundation Trust | OTHER | ["University of Cambridge", "Juvenile Diabetes Research Foundation", "National Institute for Health Research, United Kingdom", "Wellcome Trust"] | ["Type 1 Diabetes"] | ["DRUG: Aldesleukin (Proleukin)"] | Type 1 diabetes is the most common severe chronic autoimmune disease worldwide and is caused by the autoimmune (loss of self tolerance) mediated destruction of the insulin producing pancreatic beta cells thus leading to insulin deficiency and development of hyperglycaemia. Currently, medical management of type 1 diabet... | ALL | 18 Years | 50 Years | false | 2013-03 | 2014-05 | 2014-05 | 2013-04-10 | 2015-06-23 | [{"facility": "Wellcome Trust Clinical Research Facility, Addenbrooke's Hospital", "city": "Cambridge", "state": null, "country": "United Kingdom"}] | false | https://clinicaltrials.gov/study/NCT01827735 | 2026-05-14T17:51:03.641Z |
NCT00437008 | Effects of Benfotiamine and AGE on Endothelial Function in People With Diabetes | Acute Effects of a Low-AGE vs. High-AGE Meal on Postprandial Endothelial Function in People With Type 2 Diabetes Mellitus. Protective Effects of Benfotiamine | AGE-Benfo | Ruhr University of Bochum | COMPLETED | INTERVENTIONAL | ["PHASE4"] | 21 | Ruhr University of Bochum | OTHER | [] | ["Endothelial Dysfunction", "Type 2 Diabetes Mellitus"] | ["DRUG: Benfotiamine 1050mg, 3 days", "BEHAVIORAL: high-AGE vs. low-AGE meal"] | The purpose of the study is to determine whether there are differences in postprandial endothelial function following a high-AGE(Advanced Glycation End-products) meal vs. a low-AGE meal. We also intend to investigate if the therapy with 1050mg Benfotiamine for 3 days protects against the postulated deterioration of end... | ALL | 35 Years | 70 Years | false | 2004-11 | 2006-01 | null | 2007-02-19 | 2007-02-19 | [{"facility": "Heart and Diabetes Center NRW", "city": "Bad Oeynhausen", "state": null, "country": "Germany"}] | false | https://clinicaltrials.gov/study/NCT00437008 | 2026-05-14T17:51:03.685Z |
NCT05452525 | Pharmacokinetics and Safety/Tolerability Profile of CKD-379 | A Randomized, Open-label, Single Dose, 3-period, 6-treatment, Crossover Study to Compare the Pharmacokinetics and Safety/Tolerability of CKD-379 and Coadministration of D759, D745 and D150 in Healthy Subjects | null | Chong Kun Dang Pharmaceutical | COMPLETED | INTERVENTIONAL | ["PHASE1"] | 24 | Chong Kun Dang Pharmaceutical | INDUSTRY | [] | ["Type II Diabetes Mellitus"] | ["DRUG: CKD-379 I", "DRUG: CKD-379 II", "DRUG: D759+D745+D150"] | A study to compare the pharmacokinetics and safety/tolerability between CKD-379 tablet and D759, D745, D150 combination | ALL | 19 Years | 50 Years | true | 2022-07-26 | 2022-09-21 | 2022-08-27 | 2022-07-11 | 2022-10-18 | [{"facility": "Seoul National University Hospital", "city": "Seoul", "state": "Jongno-gu", "country": "South Korea"}] | false | https://clinicaltrials.gov/study/NCT05452525 | 2026-05-14T17:51:03.718Z |
NCT01387425 | Efficacy And Safety Of Smoking Cessation With Varenicline Tartrate In Diabetic Smokers: (DIASMOKE) | Efficacy And Safety Of Smoking Cessation With Varenicline Tartrate In Diabetic Smokers: A Double-Blind, Placebo-Controlled, Randomized, Trial | DIASMOKE | Universita degli Studi di Catania | COMPLETED | INTERVENTIONAL | ["NA"] | 300 | Universita degli Studi di Catania | OTHER | [] | ["Smoking Cessation", "Diabetes"] | ["DRUG: varenicline", "DRUG: placebo tablet is made of lactose"] | Objectives
This protocol is intended to provide information regarding the efficacy and safety of the nicotine partial agonist varenicline tartrate, at a dose of 1 mg twice daily, for smoking cessation in diabetic subjects who smoke. Given that a better understanding of predictors of smoking cessation can be useful in ... | ALL | 18 Years | 75 Years | false | 2011-06 | null | 2015-12 | 2011-07-04 | 2015-12-02 | [{"facility": "Centro per la Prevenzione e Cura del Tabagimso", "city": "Catania", "state": "Italy", "country": "Italy"}, {"facility": "Centro per la Prevenzione eCura del Tabagimso", "city": "Catania", "state": "Italy", "country": "Italy"}] | false | https://clinicaltrials.gov/study/NCT01387425 | 2026-05-14T17:51:03.761Z |
NCT06069076 | Diagnostic Value of Serum Cathepsin S and Chromogranin A in DKD | Diagnostic Value of Serum Cathepsin S and Chromogranin A in Diabetic Kidney Disease | null | Assiut University | NOT_YET_RECRUITING | OBSERVATIONAL | [] | 92 | Assiut University | OTHER | [] | ["Diabetic Kidney Disease"] | ["DIAGNOSTIC_TEST: cathepsin S and chromogranin A"] | 1. Evulate the diagnostic value of serum cathepsin S and chromogranin A for Diabetic kidney disease.
2. To correlate the levels of serum Cathepsin S and chromogranin A with HbA1c and eGFR in type 2 diabetic patients based on urinary Albumin- Creatinine Ratio. | ALL | 20 Years | 80 Years | true | 2023-11-01 | 2026-10-01 | 2025-10-01 | 2023-10-05 | 2023-10-13 | [] | false | https://clinicaltrials.gov/study/NCT06069076 | 2026-05-14T17:51:03.813Z |
NCT04841668 | Gut-Brain-axis: Targets for Improvement of Cognition in the Elderly | Gut-Brain-axis: Targets for Improvement of Cognition in the Elderly | SmartAge | Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta | COMPLETED | OBSERVATIONAL | [] | 50 | Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta | OTHER | [] | ["Type 2 Diabetes Mellitus"] | ["DRUG: Metformin"] | Cognitive disorders increase with age and in the presence of metabolic diseases such as Type 2 Diabetes Mellitus (T2DM). In addition, digestive disorders, changes in dietary pattern and decreased activity negatively influence the microbiome.
The hypothesis is that pharmacological intervention with metformin will modif... | ALL | 65 Years | 80 Years | false | 2021-04-10 | 2024-12-03 | 2024-12-03 | 2021-04-12 | 2026-03-31 | [{"facility": "Institut d'Investigació Biomèdica de Girona (IDIBGI)", "city": "Girona", "state": "Girona", "country": "Spain"}] | false | https://clinicaltrials.gov/study/NCT04841668 | 2026-05-14T17:51:03.861Z |
NCT03353376 | Group Versus Individual Care in Diabetes Clinic | Group Versus Individual Care in Patients With Long Standing Type 1 and Type 2 Diabetes: Non Inferiority in a One Year Prospective Study in a Tertiary Diabetes Clinic | null | Rabin Medical Center | COMPLETED | INTERVENTIONAL | ["NA"] | 60 | Rabin Medical Center | OTHER | [] | ["Diabetes Mellitus", "Group Meetings"] | ["BEHAVIORAL: group care with Empowerment model"] | In this prospective, randomized, non blinded, one center (University hospital) trial, 60 patients (28 with type 1 and 32 with type 2 diabetes) with a mean duration of diabetes of 22.5 ± 11.7 years were randomly assigned to group (6 patients per group) or individual usual care for one year. Primary end-point included ch... | ALL | 18 Years | null | false | 2010-09-13 | 2014-01-02 | 2014-01-02 | 2017-11-27 | 2017-11-27 | [] | false | https://clinicaltrials.gov/study/NCT03353376 | 2026-05-14T17:51:03.905Z |
NCT04978974 | Implications of Stress Management Program | Stress, Coping Strategies and Quality of Life Among Patients With Chronic Conditions: Implications of Stress Management Program | null | University of Gujrat | COMPLETED | INTERVENTIONAL | ["NA"] | 110 | University of Gujrat | OTHER | [] | ["Chronic Conditions, Multiple"] | ["BEHAVIORAL: Stress Management Program"] | Previous studies indicated that patients with diabetes mellitus and hypertension had higher level of perceived stress, used maladaptive coping strategies and poor health-related quality of life. Therefore, stress management program was applied to reduce their perceived stress, improve their coping strategies, improve t... | ALL | 31 Years | 60 Years | false | 2019-05-03 | 2020-12-29 | 2020-01-03 | 2021-07-27 | 2021-07-27 | [{"facility": "Jhelum Poly Clinic", "city": "Jhelum", "state": "Punjab Province", "country": "Pakistan"}] | false | https://clinicaltrials.gov/study/NCT04978974 | 2026-05-14T17:51:03.953Z |
NCT00283218 | A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, Biphasic Insulin Aspart 30, 50 and 70. | A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, Biphasic Insulin Aspart 30, 50 and 70. - A Randomised, Quadruple Cross-Over Trial | null | University of Aarhus | COMPLETED | INTERVENTIONAL | ["NA"] | 24 | University of Aarhus | OTHER | ["Novo Nordisk A/S"] | ["Type 1 Diabetes"] | ["DRUG: NovoRapid, NovoMix 30, Bifasisk Insulin Aspart 50, BIAsp70"] | The hypothesis is that an optimal formulation of fast acting and intermediary acting insulin analogues will improve post prandial glycaemic control in patients with type 1 diabetes.
OBJECTIVE:
The objective is to describe pharmacodynamic (PD) and pharmacokinetic (PK) profiles of Insulin Aspart (IAsp), Biphasic Insuli... | ALL | 18 Years | null | false | 2006-01 | 2006-08 | null | 2006-01-27 | 2006-08-08 | [{"facility": "Dept of Medicine M, Aarhus University Hospital, Nørrebrogade 44", "city": "Aarhus", "state": "C", "country": "Denmark"}] | false | https://clinicaltrials.gov/study/NCT00283218 | 2026-05-14T17:51:04.004Z |
NCT03819790 | The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians | Variability of Glucose Assessed in a Randomized Trial Comparing the Initiation of A Treatment Approach With Biosimilar Basal Insulin Analog Or a Titratable iGlarLixi combinatioN in Type 2 Diabetes Among South Asian Subjects (VARIATION 2 SA Trial) | VARIATION 2 SA | LMC Diabetes & Endocrinology Ltd. | COMPLETED | INTERVENTIONAL | ["PHASE4"] | 119 | LMC Diabetes & Endocrinology Ltd. | OTHER | [] | ["Diabetes Mellitus, Type 2"] | ["DRUG: Basal insulin glargine and lixisenatide", "DRUG: Basal insulin Basaglar/Lantus + gliclazide MR", "DRUG: Metformin"] | The overall objective of this study is to compare the effects of Soliqua, a titratable combination of insulin and GLP-1 receptor agonist in a single pen versus Glargine U100 insulin (Basaglar or Lantus) and gliclazide MR, both added to metformin, on measures of glucose variability using masked CGM data among people of ... | ALL | 18 Years | 80 Years | false | 2018-10-02 | 2019-11-19 | 2019-11-19 | 2019-01-29 | 2021-02-25 | [{"facility": "LMC Brampton", "city": "Brampton", "state": "Ontario", "country": "Canada"}, {"facility": "LMC Etobicoke", "city": "Etobicoke", "state": "Ontario", "country": "Canada"}, {"facility": "LMC Scarborough", "city": "Toronto", "state": "Ontario", "country": "Canada"}] | false | https://clinicaltrials.gov/study/NCT03819790 | 2026-05-14T17:51:04.056Z |
NCT07442110 | This Observational Study Evaluates the Clinical Outcomes of Patients With Diabetes Who Utilize a Specialized Dietary Supplements for Foot Ulcer Healing. The Study Documents the Rate of Complete Wound Closure and the Prevention of Lower Extremity Amputations in a Real-world, At-home Setting. | Observational Study of a Specialized Dietary Supplements on the Healing of Diabetic Foot Ulcers and Prevention of Amputations | null | Amar Zireg | COMPLETED | OBSERVATIONAL | [] | 35 | Amar h Zireg | OTHER | ["Self funded"] | ["Limb Salvage", "Diabetes Complication", "Dietary Supplements", "Healed Ulcer", "Wound Closure", "At Home Setting", "Diabetes Mellitus, Type 1, Type 2", "Wound Healing", "Diabetic Foot Ulcer"] | ["DIETARY_SUPPLEMENT: Diabetic foot ulcer treatment by dietary supplements"] | This observational study evaluates the clinical outcomes of patients with diabetes who utilize a specialized dietary supplements for foot ulcer healing. The study documents the rate of complete wound closure and the prevention of lower extremity amputations in a real-world, at-home setting. | ALL | 25 Years | null | false | 2025-07-05 | 2025-09-30 | 2025-09-02 | 2026-03-02 | 2026-03-04 | [{"facility": "Amar hocine Zireg", "city": "Bordj Bou Arreridj", "state": "Wilaya de Bordj Bou Arréridj", "country": "Algeria"}] | false | https://clinicaltrials.gov/study/NCT07442110 | 2026-05-14T17:51:04.097Z |
NCT00643110 | Milk as Treatment for Hypoglycemia | Milk as Treatment for Hypoglycemia | null | Creighton University | WITHDRAWN | INTERVENTIONAL | ["NA"] | 0 | Creighton University | OTHER | [] | ["Type 1 Diabetes"] | ["DRUG: D50 glucose"] | Test hypothesis that milk can raise blood sugars as well as orange juice or glucose tablets without raising blood sugars too much the way that orange juice or glucose tablets sometimes do. | ALL | 19 Years | null | true | 2008-04 | 2009-01 | 2009-01 | 2008-03-26 | 2015-03-25 | [{"facility": "Creighton Diabetes Center", "city": "Omaha", "state": "Nebraska", "country": "United States"}] | false | https://clinicaltrials.gov/study/NCT00643110 | 2026-05-14T17:51:04.139Z |
NCT05626413 | Cardiovascular Disease in Patients With Diabetes: The Silesia Diabetes-Heart Project | Cardiovascular Disease and Diabetes in Silesian Patients | null | Medical University of Silesia | UNKNOWN | OBSERVATIONAL | [] | 4,000 | Medical University of Silesia | OTHER | ["Silesian University of Technology", "Liverpool Heart and Chest Hospital NHS Foundation Trust"] | ["Diabetes Mellitus"] | [] | The project is an observational one which undertakes different, easy to obtain in everyday clinical practice, demographical, laboratory and clinical parameters of patients with diabetes in Silesian Region in Poland to predict cardiovascular disease, cardiovascular events and neuropathy using machine learning approach. | ALL | 18 Years | null | false | 2015-01-01 | 2026-01-31 | 2025-12-31 | 2022-11-23 | 2024-04-10 | [{"facility": "Department of Internal Diseases, Diabetology and Nephrology", "city": "Zabrze", "state": null, "country": "Poland"}] | false | https://clinicaltrials.gov/study/NCT05626413 | 2026-05-14T17:51:04.171Z |
NCT04583813 | Empagliflozin and Atrial Fibrillation Treatment | Efficacy of Empagliflozin in Patients With Heart Failure and Atrial Fibrillation | EMPA-AF | Miulli General Hospital | UNKNOWN | INTERVENTIONAL | ["PHASE4"] | 400 | Miulli General Hospital | OTHER | [] | ["Atrial Fibrillation", "Heart Failure", "Obesity", "Diabetes Mellitus"] | ["DRUG: Empagliflozin", "OTHER: Placebo"] | The primary purpose of this trial is to evaluate the impact of empagliflozin, as compared with placebo, in patients with diabetes mellitus or overweight, heart failure and atrial fibrillation. | ALL | 18 Years | 80 Years | false | 2021-09 | 2024-04 | 2024-01 | 2020-10-12 | 2021-04-02 | [{"facility": "Miulli General Hospital", "city": "Acquaviva delle Fonti", "state": "Bari", "country": "Italy"}] | false | https://clinicaltrials.gov/study/NCT04583813 | 2026-05-14T17:51:04.208Z |
NCT03825926 | Early Screening of Gestational Diabetes Mellitus and Prospective Cohort Study of Postpartum Follow-up | Early Screening of Gestational Diabetes Mellitus and Prospective Cohort Study of Postpartum Follow-up | null | Fifth Affiliated Hospital, Sun Yat-Sen University | UNKNOWN | OBSERVATIONAL | [] | 600 | Fifth Affiliated Hospital, Sun Yat-Sen University | OTHER | [] | ["Gestational Diabetes Mellitus"] | [] | Extraction of whole blood from 10 to 15ml at 24 weeks before pregnancy test, with a view to early detection of GDM, provides evidence for early intervention to improve maternal pregnancy outcomes and metabolic abnormalities. | FEMALE | 18 Years | 50 Years | true | 2019-06-01 | 2025-12-01 | 2025-06-01 | 2019-02-01 | 2020-03-31 | [{"facility": "the Fifth Affiliated Hospital of Sun Yat-sen University of Gynaecology and Obstetrics", "city": "Zhuhai", "state": "Guangdong", "country": "China"}] | false | https://clinicaltrials.gov/study/NCT03825926 | 2026-05-14T17:51:04.248Z |
NCT01426685 | Prognosis of Type 2 Diabetic Patients | Prediction of Cardiovascular Events in Type 2 Diabetic Patients With Coronary Artery Disease- Application of Novel Risk Markers and Technology | ARTEMIS | University of Oulu | UNKNOWN | OBSERVATIONAL | [] | 1,880 | University of Oulu | OTHER | ["The Finnish Funding Agency for Technology and Innovation"] | ["Cardiovascular Risk Assessment"] | [] | The study will include 1200 patients with type 2 diabetes and angiographically documented coronary artery disease and 600 matched non-diabetic patients without type 2 diabetes. Extensive traditional and novel risk marker tests are performed for the patients and they will be followed-up for 5 years. Sudden cardiac death... | ALL | 18 Years | 75 Years | false | 2007-08 | 2019-06 | 2019-06 | 2011-08-31 | 2019-04-19 | [{"facility": "University of Oulu", "city": "Oulu", "state": null, "country": "Finland"}] | false | https://clinicaltrials.gov/study/NCT01426685 | 2026-05-14T17:51:04.291Z |
NCT07395050 | Autologous CD6-CAR Treg Cells for Patients With Stage 3 Type 1 Diabetes | A Pilot Study to Evaluate the Safety, Tolerability, and Feasibility of Autologous Anti-CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) in Patients With Stage 3 Type 1 Diabetes | null | City of Hope Medical Center | NOT_YET_RECRUITING | INTERVENTIONAL | ["EARLY_PHASE1"] | 6 | City of Hope Medical Center | OTHER | ["National Cancer Institute (NCI)"] | ["Stage 3 Type 1 Diabetes"] | ["DRUG: AutoCD6-CAR Treg cells"] | Type 1 diabetes (T1D) is a persistent and gradually increasing genetic autoimmune disease requiring life-long management. The disease commonly impacts children. However, a quarter of cases are diagnosed in adults. The pancreatic islet beta-cells are responsible for producing insulin, a peptide hormone that is involved ... | ALL | 18 Years | 35 Years | false | 2026-06-01 | 2026-09-14 | 2026-09-14 | 2026-02-09 | 2026-05-13 | [{"facility": "City of Hope Medical Center", "city": "Duarte", "state": "California", "country": "United States"}] | false | https://clinicaltrials.gov/study/NCT07395050 | 2026-05-14T17:51:04.321Z |
NCT03457168 | Treatment of Hypertension During Sleep | A Prospective, Randomized, Open-label Clinical Trial on the Effects of Intensive Versus Conventional Control of Ambulatory-determined Asleep Systolic Blood Pressure Mean on Cardiovascular, Metabolic, and Renal Disease Risks | THADEUS | University of Vigo | RECRUITING | INTERVENTIONAL | ["NA"] | 5,320 | University of Vigo | OTHER | [] | ["Hypertension", "Hypertension, Systolic"] | ["PROCEDURE: Treatment of elevated asleep SBP mean"] | On the basis of new evidence on the relationship between achieved office blood pressure (BP) measurements (OBPM) and the risk of cardiovascular disease (CVD) morbidity and mortality documented in the SPRINT trial, the recent 2017 guidelines of the American College of Cardiology (ACC) and the American Heart Association ... | ALL | 18 Years | null | false | 2019-02-01 | 2032-12-31 | 2031-12-31 | 2018-03-07 | 2024-12-06 | [{"facility": "Complexo Hospitalario Universitario de Ourense", "city": "Ourense", "state": "Orense", "country": "Spain"}, {"facility": "CS A Estrada", "city": "A Estrada", "state": "Pontevedra", "country": "Spain"}, {"facility": "CS Panxón", "city": "Nigrán", "state": "Pontevedra", "country": "Spain"}, {"facility": "C... | false | https://clinicaltrials.gov/study/NCT03457168 | 2026-05-14T17:51:04.353Z |
NCT06683391 | Updating Preventive and Treatment Guidelines for Hypoglycemia in Individuals Living With Type 1 Diabetes | Updating pReventive and Treatment guidelinEs for Mild hypOglycemia in Individuals Living With Type 1 Diabetes During the erA of Continuous gLucose Monitoring: The REMODAL Trial | REMODAL | Institut de Recherches Cliniques de Montreal | RECRUITING | INTERVENTIONAL | ["NA"] | 32 | Institut de Recherches Cliniques de Montreal | OTHER | [] | ["Type 1 Diabetes"] | ["BEHAVIORAL: Oral Carbohydrate (CHO) Administration for Hypoglycemia Prevention and Treatment"] | The REMODAL trial is a randomized crossover study aiming to update treatment guidelines for mild hypoglycemia in people with Type 1 diabetes using continuous glucose monitoring (CGM) technology. The study will assess whether treating mild hypoglycemia proactively (at a glucose threshold of 5.0 mmol/L) with lower doses ... | ALL | 18 Years | null | false | 2025-02-06 | 2027-12-31 | 2026-12-31 | 2024-11-12 | 2025-02-25 | [{"facility": "Institut de recherches cliniques de Montréal", "city": "Montreal", "state": "Quebec", "country": "Canada"}, {"facility": "Montreal Clinical Research Institute", "city": "Montreal", "state": "Quebec", "country": "Canada"}] | false | https://clinicaltrials.gov/study/NCT06683391 | 2026-05-14T17:51:04.389Z |
NCT03915990 | Middle Cerebral and Umbilical Arteries Doppler Indices in the Prediction of Adverse Neonatal Outcome Among Diabetic Pregnant Women | Middle Cerebral and Umbilical Arteries Doppler Indices in Pregestational Diabetic Versus Normal Pregnancies and Their Values in Predicting Adverse Neonatal Outcome | null | Cairo University | UNKNOWN | INTERVENTIONAL | ["NA"] | 120 | Cairo University | OTHER | [] | ["Diabetes Mellitus, Type 1"] | ["DIAGNOSTIC_TEST: umbilical and middle cerebral artery Doppler"] | 120 patients will be included and divided into two groups; Control group that will include 60 healthy pregnant women and Study group that will include 60 pregestational diabetic pregnant patients which furtherly will be subdivided into two groups according to HbA1C levels namely; controlled diabetics ( will include 30 ... | FEMALE | 18 Years | 40 Years | false | 2019-07-01 | 2020-12 | 2020-12 | 2019-04-16 | 2020-11-10 | [{"facility": "kasr elainy hospital (Faculty of Medicine - Cairo University)", "city": "Cairo", "state": null, "country": "Egypt"}] | false | https://clinicaltrials.gov/study/NCT03915990 | 2026-05-14T17:51:04.424Z |
NCT00476710 | Effects of Colesevelam HCl On Bile Acid Kinetics | Effects of Colesevelam HCl On Bile Acid Pools And Kinetic Parameters in Normal Subjects, Subjects With Impaired Glucose Tolerance, And Subjects With Type 2 Diabetes Mellitus | null | KineMed | COMPLETED | OBSERVATIONAL | [] | 36 | KineMed | INDUSTRY | ["Daiichi Sankyo", "University Medical Center Groningen", "Diabetes & Glandular Disease Research Associates"] | ["Type 2 Diabetes Mellitus", "Impaired Glucose Tolerance"] | ["DRUG: Colesevelam HCl"] | This project will compare the amount of bile acids and their kinetics in overweight and obese people with normal glucose metabolism, impaired glucose tolerance and frank type 2 diabetes. We hypothesize that bile acids will behave differently in these groups. We will also explore the effects of Colesevelam HCl, a medici... | ALL | 40 Years | 60 Years | true | 2007-05 | 2009-04 | 2009-04 | 2007-05-22 | 2015-04-01 | [{"facility": "Diabetes & Glandular Disease Research Associates, Inc.", "city": "San Antonio", "state": "Texas", "country": "United States"}] | false | https://clinicaltrials.gov/study/NCT00476710 | 2026-05-14T17:51:04.462Z |
NCT01659697 | Diabetes Prevention in Prediabetic Patients | Diabetes Prevention in Patients Aged 25-55 From Ethiopian Origin With Prediabetes: Evaluation of Feasibility and Efficacy of Intensive or Less Intensive Lifestyle Intervention | DPEP | Meir Medical Center | UNKNOWN | OBSERVATIONAL | [] | 200 | Meir Medical Center | OTHER | ["Clalit Health Services"] | ["Ethnic Group", "Young Adults", "Prediabetes", "Community Health Services"] | ["BEHAVIORAL: intensive lifestyle counseling"] | This study will evaluate the feasibility and efficacy of two interventions of lifestyle ( intensive and less intensive) to prevent diabetes in patients from Ethiopian origin, aged 25 to 55 years old with prediabetes living in Israel and insured by Clalit Health Services in the Central district, using resources existing... | ALL | 25 Years | 55 Years | false | 2012-08 | 2015-07 | 2014-12 | 2012-08-08 | 2012-08-08 | [{"facility": "Central district Clalit Health Services", "city": "Rishon LeZiyyon", "state": null, "country": "Israel"}] | false | https://clinicaltrials.gov/study/NCT01659697 | 2026-05-14T17:51:04.605Z |
NCT00974090 | Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes | A Phase III Study of MP-513 in Combination With Sulfonylurea in Japanese Patients With Type 2 Diabetes Mellitus | null | Tanabe Pharma Corporation | COMPLETED | INTERVENTIONAL | ["PHASE3"] | 194 | Tanabe Pharma Corporation | INDUSTRY | [] | ["Type 2 Diabetes Mellitus"] | ["DRUG: Placebo / Teneli (Teneligliptin) + SU (Sulfonylurea)", "DRUG: Teneli / Teneli + SU"] | The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) in combination with Sulfonylurea in patients with type 2 Diabetes for 12 weeks administration and to evaluate the safety and efficacy of MP-513 in combination with Sulfonylurea with an extension treatment for up to 52 weeks. | ALL | 20 Years | 75 Years | false | 2009-09 | 2011-03 | 2011-03 | 2009-09-10 | 2026-01-05 | [{"facility": null, "city": "Sapporo", "state": "Hokkaido", "country": "Japan"}] | true | https://clinicaltrials.gov/study/NCT00974090 | 2026-05-14T17:51:04.688Z |
NCT01583790 | Factors Influencing the Positive Outcome of Bariatric Surgery for Morbidly Obese Patients | A Prospective Trial for Laparoscopic Adjustable Gastric Banding in Morbidly Obese Patients: Report on Weight Loss, Metabolic Changes and Quality of Life | null | Assuta Hospital Systems | UNKNOWN | OBSERVATIONAL | [] | 2,000 | Assuta Hospital Systems | OTHER | [] | ["Morbid Obesity", "Diabetes", "Hypertension"] | [] | The purpose of this study is to report data with patients after bariatric surgery. | ALL | 14 Years | 65 Years | false | 2012-01 | 2020-01 | 2019-01 | 2012-04-24 | 2018-01-25 | [{"facility": "Assuta Medical Center", "city": "Tel Aviv", "state": null, "country": "Israel"}] | false | https://clinicaltrials.gov/study/NCT01583790 | 2026-05-14T17:51:04.712Z |
NCT00746460 | The Healthy Options Feasibility Study | The Effectiveness of CVD Risk Profiles When Used by Allied Health Care Providers (HCP) Within a "Groupe de Médecine de Famille": The Healthy Options Feasibility Study. | null | McGill University | COMPLETED | INTERVENTIONAL | ["NA"] | 50 | McGill University | OTHER | ["Pfizer"] | ["Obesity", "Sedentary Lifestyle", "Dyslipidemia", "Hypertension", "Cigarette Smoking", "Diabetes"] | ["BEHAVIORAL: CVD risk profile"] | The investigators hypothesize that having health care providers other than physicians within a "Groupe de Médecine de Famille" conduct cardiovascular risk assessments and teach lifestyle interventions to primary prevention patients will increase the likelihood that patients will adopt and maintain healthy lifestyles. T... | ALL | 30 Years | 79 Years | false | 2008-06 | 2009-10 | 2009-04 | 2008-09-04 | 2014-01-14 | [{"facility": "McGill Cardiovascular Health Improvement Program", "city": "Montreal", "state": "Quebec", "country": "Canada"}] | false | https://clinicaltrials.gov/study/NCT00746460 | 2026-05-14T17:51:04.762Z |
NCT05463744 | A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy | A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy | QWINT-5 | Eli Lilly and Company | COMPLETED | INTERVENTIONAL | ["PHASE3"] | 692 | Eli Lilly and Company | INDUSTRY | [] | ["Type 1 Diabetes", "Diabetes"] | ["DRUG: Insulin Efsitora Alfa", "DRUG: Insulin Degludec"] | The main purpose of this study is to measure the safety and efficacy of insulin efsitora alfa (LY3209590) compared with insulin degludec in participants with type 1 diabetes treated with multiple daily injection therapy. | ALL | 18 Years | null | false | 2022-08-12 | 2024-05-07 | 2024-05-07 | 2022-07-19 | 2025-06-24 | [{"facility": "John Muir Physician Network Research Center", "city": "Concord", "state": "California", "country": "United States"}, {"facility": "Valley Research", "city": "Fresno", "state": "California", "country": "United States"}, {"facility": "Catalina Research Institute, LLC", "city": "Montclair", "state": "Califo... | true | https://clinicaltrials.gov/study/NCT05463744 | 2026-05-14T17:51:04.834Z |
NCT03331432 | Effects of Dietary Supplement Tauroursodeoxycholic Acid on Vascular Function | Targeting Endoplasmic Reticulum Stress to Correct Vascular Insulin Resistance and Glycemic Dysregulation | null | University of Missouri-Columbia | COMPLETED | INTERVENTIONAL | ["NA"] | 8 | University of Missouri-Columbia | OTHER | [] | ["Type 2 Diabetes Mellitus"] | ["DIETARY_SUPPLEMENT: Tauroursodeoxycholic acid", "DIETARY_SUPPLEMENT: Placebo"] | The purpose of the present study is to determine if use of dietary supplement tauroursodeoxycholic acid enhances insulin-stimulated leg blood flow and glucose disposal. | ALL | 20 Years | 65 Years | false | 2015-10-28 | 2018-02-14 | 2017-08-15 | 2017-11-06 | 2018-02-19 | [{"facility": "University of Missouri", "city": "Columbia", "state": "Missouri", "country": "United States"}] | false | https://clinicaltrials.gov/study/NCT03331432 | 2026-05-14T17:51:04.875Z |
NCT05785832 | A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes | A Randomized Trial Evaluating the Efficacy and Safety of Control-IQ+ Technology in Adults With Type 2 Diabetes Using Basal-Bolus Insulin Therapy (2IQP) | 2IQP | Tandem Diabetes Care, Inc. | COMPLETED | INTERVENTIONAL | ["NA"] | 319 | Tandem Diabetes Care, Inc. | INDUSTRY | ["Jaeb Center for Health Research"] | ["Type 2 Diabetes Treated With Insulin"] | ["DEVICE: t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM", "DEVICE: Standard Therapy plus continuous glucose monitoring (CGM)"] | A randomized controlled trial (RCT) to assess the safety and efficacy of use of Control-IQ+ technology in adults with type 2 diabetes using basal-bolus insulin therapy. | ALL | 18 Years | null | false | 2023-06-01 | 2024-09-24 | 2024-09-24 | 2023-03-27 | 2026-02-19 | [{"facility": "Hoag Memorial Hospital Presbyterian", "city": "Newport Beach", "state": "California", "country": "United States"}, {"facility": "Emory University School of Medicine", "city": "Atlanta", "state": "Georgia", "country": "United States"}, {"facility": "Rocky Mountain Clinical Research", "city": "Idaho Falls"... | true | https://clinicaltrials.gov/study/NCT05785832 | 2026-05-14T17:51:04.914Z |
NCT03314714 | Duality of Lipids: the Athlete's Paradox | The Dual Role of Intramyocellular Lipids in Mediating Insulin Resistance: Assessing the Mechanisms of the Athlete's Paradox | LIDDIA | German Diabetes Center | COMPLETED | INTERVENTIONAL | ["NA"] | 100 | German Diabetes Center | OTHER | ["Maastricht University"] | ["Insulin Resistance, Diabetes", "Lipid Metabolism Disorders"] | ["PROCEDURE: Acute bout of endurance exercise"] | Accumulation of intramyocellular lipids (IMCLs) due to increased supply of fatty acids can induce defects in the insulin signaling cascade, causing skeletal muscle insulin resistance. However, the causes for muscle insulin resistance are not well understood. The association of elevated IMCLs and insulin resistance has ... | ALL | 18 Years | 69 Years | true | 2017-04-03 | 2023-06-01 | 2023-06-01 | 2017-10-19 | 2023-06-13 | [{"facility": "German Diabetes Center", "city": "Düsseldorf", "state": "North Rhine-Westphalia", "country": "Germany"}, {"facility": "Maastricht University", "city": "Maastricht", "state": null, "country": "Netherlands"}] | false | https://clinicaltrials.gov/study/NCT03314714 | 2026-05-14T17:51:04.940Z |
NCT06760416 | Online Diabetic Foot Support Program- Care Kit | Effect of Online Diabetic Foot Support Program (DiaFootSuP) and Care Kit on Diabetic Foot Care Outcomes: Randomized Controlled Trial | DiaFootSuP | Dokuz Eylul University | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | ["NA"] | 62 | Merve GÃnbaAY | OTHER | ["The Scientific and Technological Research Council of Turkey"] | ["Diabetes Mellitus", "Diabetic Foot Ulcer", "Diabetic Foot"] | ["OTHER: Nursing Education"] | The aim of this project is to examine the effects of the online diabetic foot support program (DiaFootSuP) and care kit applied to type 2 diabetic individuals who have previously had a diabetic foot ulcer on diabetic foot outcomes (diabetic foot knowledge level, foot care behavior level, foot care self-efficacy level, ... | ALL | 18 Years | null | false | 2024-11-01 | 2025-03-31 | 2024-12-27 | 2025-01-06 | 2025-01-06 | [{"facility": "Dokuz Eylül University", "city": "Izmir", "state": "Buca", "country": "Turkey (Türkiye)"}] | false | https://clinicaltrials.gov/study/NCT06760416 | 2026-05-14T17:51:04.983Z |
NCT04024306 | Steroid-induced Diabetes Mellitus in Systemic Lupus Erythematosus (SLE) Patients | Steroid-induced Diabetes Mellitus in Systemic Lupus Erythematosus (SLE) Patients | null | Assiut University | UNKNOWN | OBSERVATIONAL | [] | 120 | Assiut University | OTHER | [] | ["System; Lupus Erythematosus"] | [] | The aim of the study is to determine the prevalence of steroid-induced diabetes mellitus (SDM) among systemic lupus erythematosus (SLE) patients and identify and assess the associated risk factors . | ALL | 18 Years | 75 Years | false | 2022-09-01 | 2024-04-20 | 2024-04-01 | 2019-07-18 | 2023-07-19 | [{"facility": "Assiut university hospital", "city": "Asyut", "state": null, "country": "Egypt"}] | false | https://clinicaltrials.gov/study/NCT04024306 | 2026-05-14T17:51:04.999Z |
NCT00607906 | First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050 | A Single-blinded, Randomized, Placebo-controlled, Staggered-parallel, Escalating Single Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered SB756050 in Healthy Volunteers and in Subjects With Type 2 Diabetes Mellitus | null | GlaxoSmithKline | COMPLETED | INTERVENTIONAL | ["PHASE1"] | 36 | GlaxoSmithKline | INDUSTRY | [] | ["Diabetes Mellitus, Type 2"] | ["DRUG: SB-756050 immediate release capsule", "DRUG: SB-756050 modified release capsule", "DRUG: Placebo"] | This study will use single escalating doses of SB756050 to assess safety, pharmacokinetics, and pharmacodynamics in healthy volunteers and in subjects with Type 2 Diabetes Mellitus. | ALL | 18 Years | 60 Years | true | 2007-11-16 | 2008-03-10 | 2008-03-10 | 2008-02-06 | 2017-09-06 | [{"facility": "GSK Investigational Site", "city": "Minneapolis", "state": "Minnesota", "country": "United States"}] | false | https://clinicaltrials.gov/study/NCT00607906 | 2026-05-14T17:51:05.053Z |
NCT05251506 | The Evaluation of Laser Lancing Devices in Adult Type 2 Diabetes Patients | The Evaluation of Laser Lancing Devices in Constructing Self-management Systems for Chronic Diseases in Adult Diabetes Patients | null | Korea University Guro Hospital | UNKNOWN | INTERVENTIONAL | ["NA"] | 80 | Korea University Guro Hospital | OTHER | ["Korea Medical Device Development Fund"] | ["Type 2 Diabetes"] | ["DEVICE: laser lancing device or lancet for blood glucose level measurement"] | Self monitoring of blood glucose level is crucial in diabetes management, but currently available methods, lancet, have shown low compliance of self monitoring of blood glucose because of pain, keratinization of finger tip, secondary infection. The purpose of this study is evaluating laser lancing device which cause mu... | ALL | 20 Years | 79 Years | false | 2021-08-10 | 2022-12-31 | 2022-03-31 | 2022-02-22 | 2022-02-22 | [{"facility": "Korea University medical center", "city": "Seoul", "state": null, "country": "South Korea"}] | false | https://clinicaltrials.gov/study/NCT05251506 | 2026-05-14T17:51:05.121Z |
NCT02898506 | Incretin-based Therapy in Late Preclinical Type 1 Diabetes | Incretin-based Therapy in Late Preclinical Type 1 Diabetes | null | University of Oulu | COMPLETED | INTERVENTIONAL | ["PHASE2"] | 13 | University of Oulu | OTHER | ["Oulu University Hospital", "Tampere University Hospital", "Turku University Hospital", "Skane University Hospital"] | ["Type 1 Diabetes"] | ["DRUG: Victoza®", "DRUG: Placebo"] | The objective of the trial is to study whether daily treatment with liraglutide improves endogenous insulin secretion, postpones progression to overt Type 1 diabetes, and is tolerable and safe in subjects aged 10-30 years, who are positive for multiple islet autoantibodies and have dysglycemia. | ALL | 10 Years | 30 Years | false | 2016-03 | 2021-06 | 2021-06 | 2016-09-13 | 2022-01-25 | [{"facility": "University of Oulu and Oulu University Hospital, Dept of Children and Adolescents", "city": "Oulu", "state": null, "country": "Finland"}, {"facility": "University of Tampere and Tampere University Hospital", "city": "Tampere", "state": null, "country": "Finland"}, {"facility": "University of Turku and Tu... | false | https://clinicaltrials.gov/study/NCT02898506 | 2026-05-14T17:51:05.147Z |
NCT04361552 | Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection) | Tociluzumab for Cytokine Release Syndrome With SARS-CoV-2: An Open-Labeled, Randomized Phase 3 Trial | null | Emory University | WITHDRAWN | INTERVENTIONAL | ["PHASE3"] | 0 | Emory University | OTHER | ["National Cancer Institute (NCI)"] | ["Cerebrovascular Accident", "Chronic Obstructive Pulmonary Disease", "Chronic Renal Failure", "Coronary Artery Disease", "Diabetes Mellitus", "Malignant Neoplasm", "SARS Coronavirus 2 Infection"] | ["OTHER: Best Practice", "BIOLOGICAL: Tocilizumab"] | This phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS is a potentially serious disorder caused by the release of an excessive amount of substance that is made by cells of the... | ALL | 18 Years | null | false | 2020-04-07 | 2020-06-02 | 2020-06-02 | 2020-04-24 | 2020-06-18 | [{"facility": "Emory University Hospital/Winship Cancer Institute", "city": "Atlanta", "state": "Georgia", "country": "United States"}] | false | https://clinicaltrials.gov/study/NCT04361552 | 2026-05-14T17:51:05.194Z |
NCT05184049 | Effects of Epalrestat on Peripheral Neuropathy and Central Nervous System in Diabetic Patients | Effects of Epalrestat on Peripheral Neuropathy and Central Nervous System in Diabetic Patient | null | Xiangya Hospital of Central South University | UNKNOWN | INTERVENTIONAL | ["PHASE4"] | 72 | Xiangya Hospital of Central South University | OTHER | [] | ["Diabetes"] | ["DRUG: Epalrestat,Mecobalamin", "DRUG: Mecobalamin"] | This study evaluated the efficacy of epalrestat in diabetic peripheral neuropathy and its effects on the central nervous system in diabetic peripheral neuropathy subjects. | ALL | 18 Years | 65 Years | false | 2022-01 | 2023-10 | 2023-10 | 2022-01-11 | 2022-01-11 | [{"facility": "Xiangya Hospital of Central South University", "city": "Changsha", "state": "Hunan", "country": "China"}] | false | https://clinicaltrials.gov/study/NCT05184049 | 2026-05-14T17:51:05.210Z |
NCT00806338 | An Ascending Multi-Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers | A Phase I, Double-Blind, Randomized, Placebo-Controlled Ascending IV Multiple Dose Tolerance and Pharmacokinetic Study of Trodusquemine (MSI-1436) in Obese or Overweight Type 2 Diabetic Volunteers | null | Genaera Corporation | COMPLETED | INTERVENTIONAL | ["PHASE1"] | 22 | Genaera Corporation | INDUSTRY | [] | ["Diabetes Mellitus", "Obesity"] | ["DRUG: Trodusquemine (MSI-1436)", "DRUG: Placebo"] | The purpose of this study is to evaluate the safety and tolerance of multiple intravenous (through a vein) doses of trodusquemine (MSI-1436) in obese or overweight, type 2 diabetics. | ALL | 18 Years | 65 Years | false | 2008-11 | 2009-04 | 2009-04 | 2008-12-10 | 2009-04-15 | [{"facility": "Cetero Research", "city": "Miami Gardens", "state": "Florida", "country": "United States"}, {"facility": "dgd Research", "city": "San Antonio", "state": "Texas", "country": "United States"}] | false | https://clinicaltrials.gov/study/NCT00806338 | 2026-05-14T17:51:05.234Z |
NCT07258758 | Diabetes Intervention Involving Person-centred Nutritional Education | Diabetes Intervention Involving Person-centred Nutritional Education (DINE) - Exploring the Benefits and Challenges of a Person-centred Education on the Nordic Diet for Adults With Type 1 Diabetes. | DINE | Umeå University | RECRUITING | INTERVENTIONAL | ["NA"] | 54 | Umeå University | OTHER | ["Lasarettet i Enköping"] | ["Diabetes Type 1"] | ["BEHAVIORAL: Dietary intervention"] | The overall objective for this project is to evaluate the effects of a person-centred education intervention to promote a healthy, sustainable Nordic diet compared with the current practice of providing short dietary information on health outcomes of adults with Type 1 diabetes. The study will measure the intervention'... | ALL | 18 Years | null | false | 2025-09-01 | 2027-06 | 2027-06 | 2025-12-02 | 2025-12-12 | [{"facility": "Hospital of Enköping", "city": "Enköping", "state": "Uppland", "country": "Sweden"}] | false | https://clinicaltrials.gov/study/NCT07258758 | 2026-05-14T17:51:05.277Z |
NCT03574558 | Personalized Automated Determination of Insulin Pump Setting for Subjects With Type 1 Diabetes Switching From MDI to Pump Therapy and Vice Versa- Safety and Efficacy Feasibility Study | Personalized Automated Determination of Insulin Pump Setting for Subjects With Type 1 Diabetes Switching From MDI to Pump Therapy and Vice Versa- Safety and Efficacy Feasibility Study | null | Rabin Medical Center | COMPLETED | INTERVENTIONAL | ["NA"] | 28 | Rabin Medical Center | OTHER | ["Juvenile Diabetes Research Foundation", "Jaeb Center for Health Research", "DreaMed", "University of Padova"] | ["Type1diabetes"] | ["DEVICE: MD-Logic Switch Advisor"] | The "MD-Logic Switch Advisor" is a software product that is designed to assist in insulin dosage decision making and has two components:
A. MD-Logic Switch Advisor for initiation of pump therapy - this product is designed to assist physicians in decision making when initiating insulin pump therapy.
B. MD-Logic Switch... | ALL | 6 Years | 30 Years | false | 2018-08-01 | 2019-11-25 | 2019-11-25 | 2018-07-02 | 2019-12-27 | [{"facility": "Schnider children's medical center", "city": "Petah Tikva", "state": null, "country": "Israel"}] | false | https://clinicaltrials.gov/study/NCT03574558 | 2026-05-14T17:51:05.316Z |
NCT00516958 | Pilot Study of the Safety and Clinical Efficacy of Topical Dermacyn™ Wound Care to Treat Mild Diabetic Foot Infections | An Open Label, Three Arm, Pilot Study of the Safety and Clinical Efficacy of Topical Dermacyn™ Wound Care vs. Oral Levofloxacin vs. Combined Therapy for Mild Diabetic Foot Infections | null | Oculus Innovative Sciences, Inc. | COMPLETED | INTERVENTIONAL | ["PHASE2"] | 65 | Oculus Innovative Sciences, Inc. | INDUSTRY | [] | ["Foot Ulcer, Diabetic"] | ["DRUG: Topical Dermacyn", "DRUG: Topical Dermacyn and Levofloxacin", "DRUG: Topical Saline and Levofloxacin"] | To compare the rates of clinical success of Topical Dermacyn™ vs. Oral Levofloxacin vs. Combined therapy, in subjects with mild diabetic foot infections in non-ischemic ulcers. | ALL | 18 Years | null | false | 2007-05 | 2007-12 | 2007-12 | 2007-08-16 | 2008-01-14 | [{"facility": null, "city": "Tucson", "state": "Arizona", "country": "United States"}, {"facility": null, "city": "La Jolla", "state": "California", "country": "United States"}, {"facility": null, "city": "Los Angeles", "state": "California", "country": "United States"}, {"facility": null, "city": "San Diego", "state":... | false | https://clinicaltrials.gov/study/NCT00516958 | 2026-05-14T17:51:05.347Z |
NCT03510078 | Intensive Versus Conventional Hyperglycemic Control in Hospitalized Non-critically Ill Patients | Intensive Versus Conventional Hyperglycemic Control in Hospitalized Non-critically Ill Patients | null | Rabin Medical Center | COMPLETED | INTERVENTIONAL | ["NA"] | 600 | Rabin Medical Center | OTHER | [] | ["Diabetes Mellitus", "Non-critically Ill Patients"] | ["DRUG: Insulin"] | Hyperglycemia is a common condition among hospitalized patients. The occurrence of severe hyperglycemia is associated with increased morbidity and mortality in several populations. Several trials assessed the benefits of aggressive versus conventional glucose control. These studies evaluated different patient populatio... | ALL | 18 Years | 120 Years | false | 2018-04-17 | 2025-12-10 | 2025-07-01 | 2018-04-27 | 2026-04-30 | [{"facility": "Rabin Medical Center", "city": "Petah Tikva", "state": "Israel", "country": "Israel"}, {"facility": "Soroka University Medical Center", "city": "Beersheba", "state": null, "country": "Israel"}, {"facility": "Rambam Medical Center", "city": "Haifa", "state": null, "country": "Israel"}, {"facility": "Shami... | false | https://clinicaltrials.gov/study/NCT03510078 | 2026-05-14T17:51:05.400Z |
NCT01293578 | Study to Test Use of a Decision Aid in a Clinical Visit to Help Patients Choose a Diabetes Medication | Translating Information on Comparative Effectiveness Into Practice (TRICEP) | TRICEP | Mayo Clinic | COMPLETED | INTERVENTIONAL | ["NA"] | 550 | Mayo Clinic | OTHER | [] | ["Type 2 Diabetes Mellitus"] | ["OTHER: Diabetes Medication Choice Cards"] | The goal of this study is to test the relative merits of a decision aid for diabetes medications that we have developed - Diabetes Medication Choice Cards- versus usual care in translating comparative effectiveness research (CER) into real world clinics. This study will involve about 20 primary care practice sites affi... | ALL | 18 Years | null | true | 2011-01 | 2015-06 | 2015-06 | 2011-02-10 | 2022-09-28 | [{"facility": "Albert Lea Medical Center", "city": "Albert Lea", "state": "Minnesota", "country": "United States"}, {"facility": "Mayo Clinic Kasson", "city": "Kasson", "state": "Minnesota", "country": "United States"}, {"facility": "Mayo Clinic Health System- Immanual St. Joseph's", "city": "Mankato", "state": "Minnes... | false | https://clinicaltrials.gov/study/NCT01293578 | 2026-05-14T17:51:05.417Z |
NCT05659043 | Glycation of apoA-I and Diabetic Atherogenesis | The Impact of Glycation Modification of apoA-I on HDL Function and Atherogenesis in Type Diabetes Mellitus | null | Ruijin Hospital | UNKNOWN | OBSERVATIONAL | [] | 2,000 | Ruijin Hospital | OTHER | [] | ["Diabetes Mellitus, Type 2"] | ["OTHER: overnight fasting"] | The goal of this study is to determine the relationship of apoprotein A-1 (apoA-I) glycation and development of diabetic atherosclerosis.
ApoA-I is crucial for reverse cholesterol transport and anti-inflammation/anti-atherosclersis functions of HDL. However, apoA-I is easily subjected to non-enzymatic glycation modifi... | ALL | 18 Years | 90 Years | false | 2017-01 | 2023-12 | 2021-12 | 2022-12-21 | 2022-12-21 | [{"facility": "Ruijin Hospital, Shanghai Jiaotong University School of Medicine", "city": "Shanghai", "state": "Shanghai Municipality", "country": "China"}] | false | https://clinicaltrials.gov/study/NCT05659043 | 2026-05-14T17:51:05.501Z |
NCT05767255 | Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue | Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue | null | Hospital Universitario San Ignacio | UNKNOWN | INTERVENTIONAL | ["PHASE3"] | 66 | Hospital Universitario San Ignacio | OTHER | [] | ["Diabetes Mellitus, Type 2 Treated With Insulin"] | ["DRUG: insulin degludec + liraglutide", "DRUG: Insulin Glargine - Insulin Aspart"] | The association of insulin degludec with liraglutide in the same device (IDegLira) is a potent but at the same time safe drug that reduces the risk of hypoglycemia when compared to a basal or basal-bolus insulin schedule.
The DUAL (Dual Action of Liraglutide and Insulin Degludec) studies are the pivotal studies of thi... | ALL | 18 Years | null | false | 2022-12-01 | 2023-08-30 | 2023-08-30 | 2023-03-14 | 2023-03-14 | [{"facility": "Hospital Universitario San Ignacio", "city": "Bogotá", "state": null, "country": "Colombia"}] | false | https://clinicaltrials.gov/study/NCT05767255 | 2026-05-14T17:51:05.540Z |
NCT05959135 | Gastric Ultrasound in Diabetic and Non-Diabetic Pregnant Women | Ultrasound Evaluation of Gastric Content in Diabetic and Non-Diabetic Term Pregnant Women: An Observational Study | null | Sisli Hamidiye Etfal Training and Research Hospital | COMPLETED | OBSERVATIONAL | [] | 80 | Sisli Hamidiye Etfal Training and Research Hospital | OTHER | [] | ["Gastric Ultrasonography", "Gastric Volume", "Pulmonary Aspiration", "Diabetic Pregnancy", "Fasting"] | ["DEVICE: Gastric ultrasonography"] | Perioperative aspiration is particularly concerning in pregnant women due to anatomical changes. To mitigate this risk, pre-anesthetic fasting is recommended, with varying guidelines. Gastric ultrasound can non-invasively assess stomach contents, and mathematical models help estimate stomach volumes using the gastric a... | FEMALE | 18 Years | 40 Years | true | 2023-07-26 | 2023-12-25 | 2023-12-10 | 2023-07-25 | 2023-12-29 | [{"facility": "Sisli Hamidiye Etfal Training and Research Hospital", "city": "Sarıyer", "state": "Istanbul", "country": "Turkey (Türkiye)"}] | false | https://clinicaltrials.gov/study/NCT05959135 | 2026-05-14T17:51:05.560Z |
NCT06912035 | Efficacy of Diacerein Supplementation on Interleukin-1β, Hs-CRP, TNF-α Levels and Glycemic Control in Uncontrolled Type 2 Diabetes Mellitus Patients at Dr. Mohammad Hoesin General Hospital Palembang | EFFICACY OF DIACEREIN ADDITION ON INTERLEUKIN-1Β, HS-CRP, TNF-Α LEVELS AND GLYCEMIC CONTROL IN UNCONTROLLED TYPE 2 DIABETES MELLITUS PATIENTS AT DR. MOHAMMAD HOESIN GENERAL HOSPITAL PALEMBANG | null | Universitas Sriwijaya | COMPLETED | INTERVENTIONAL | ["PHASE2", "PHASE3"] | 34 | Universitas Sriwijaya | OTHER | ["Indonesia Endowment Fund for Education (LPDP), Ministry of Finance Republik of Indonesia"] | ["Uncontrolled Diabetes", "Diabetes Mellitus Type 2"] | ["DRUG: Diacerein 50 mg Capsule", "DRUG: Placebo"] | The goal of this clinical trial is to learn if diacerein supplementation can help improve inflammation and glycemic control in adults with uncontrolled type 2 diabetes. It will also study the safety and tolerability of diacerein. The main questions it aims to answer are:
* Does diacerein lower levels of inflammatory m... | ALL | 60 Years | 60 Years | false | 2024-06-21 | 2024-11-08 | 2024-11-08 | 2025-04-04 | 2025-04-04 | [{"facility": "Universitas Sriwijaya", "city": "Palembang", "state": "South Sumatera", "country": "Indonesia"}] | false | https://clinicaltrials.gov/study/NCT06912035 | 2026-05-14T17:51:05.603Z |
NCT01973374 | Sugar Text: A Randomized Controlled Trial of a Text Message Intervention for Women With Diabetes in Pregnancy | Sugar Text: A Randomized Controlled Trial of a Text Message Intervention for Women With Diabetes in Pregnancy | Sugar Text | University of Pennsylvania | COMPLETED | INTERVENTIONAL | ["NA"] | 30 | University of Pennsylvania | OTHER | [] | ["Diabetes in Pregnancy", "Gestational Diabetes", "Texting Interventions"] | ["BEHAVIORAL: Text Message Intervention"] | Maternal diabetes in pregnancy can negatively impact fetal well-being and contribute to adverse pregnancy outcomes. Much of the morbidity associated with diabetes in pregnancy can be minimized with tight glucose control. A number of studies in non-pregnant populations have highlighted the feasibility, acceptability and... | FEMALE | 18 Years | 50 Years | false | 2013-01 | 2014-04 | 2014-04 | 2013-10-31 | 2015-02-20 | [{"facility": "Hospital of the University of Pennsylvania", "city": "Philadelphia", "state": "Pennsylvania", "country": "United States"}] | false | https://clinicaltrials.gov/study/NCT01973374 | 2026-05-14T17:51:05.645Z |
NCT02607410 | Sitagliptin (DPP-4 Inhibitor) and NPH Insulin in Patients With T2D | Short and Long Term Effects of a Dypeptidil-peptidase-4 Versus Bedtime NPH Insulin as add-on Therapy in Patients With Type 2 Diabetes | null | University of Sao Paulo General Hospital | COMPLETED | INTERVENTIONAL | ["PHASE4"] | 40 | University of Sao Paulo General Hospital | OTHER | ["Fundação de Amparo à Pesquisa do Estado de São Paulo"] | ["Type 2 Diabetes Mellitus"] | ["DRUG: sitagliptin", "DRUG: NPH insulin"] | To compare the short and long term effects of inhibitor of the DPP-IV enzyme, sitagliptin , with bedtime NPH insulin in patients with T2D inadequately controlled with sulphonylurea plus biguanide: effects on beta cell function and on metabolic profile. | ALL | 35 Years | 70 Years | false | 2010-01 | 2014-07 | 2012-01 | 2015-11-18 | 2015-11-18 | [{"facility": "University of Sao Paulo General Hospital", "city": "São Paulo", "state": "São Paulo", "country": "Brazil"}] | false | https://clinicaltrials.gov/study/NCT02607410 | 2026-05-14T17:51:05.688Z |
NCT07147010 | Evaluation of Correlations Between Volatile Organic Compounds and Venous Blood Glucose in Subjects With Type 2 Diabetes | Evaluation of Correlations Between Volatile Organic Compounds (VOCs) Spectra Measured With GC-IMS and MOx-sensors and Venous Blood Glucose in Subjects With Type 2 Diabetes | Evo | DCB Research AG | COMPLETED | INTERVENTIONAL | ["NA"] | 20 | DCB Research AG | OTHER | ["Insel Gruppe AG, University Hospital Bern", "BOYDSENSE"] | ["Type 2 Diabetes"] | ["DEVICE: MIB Breath Analyzer"] | The goal of this study is to evaluate correlations between VOCs in the breath and venous blood glucose values in various glycaemic states in people living with Type 2 Diabetes.
VOCs are measured with a gold-standard GC-IMS device and a prototype of a novel breath analyzer. Participants will be exposed to different blo... | ALL | 45 Years | 70 Years | false | 2024-10-01 | 2025-11-27 | 2025-03-30 | 2025-08-28 | 2025-12-09 | [{"facility": "Inselspital Bern", "city": "Bern", "state": null, "country": "Switzerland"}] | false | https://clinicaltrials.gov/study/NCT07147010 | 2026-05-14T17:51:05.735Z |
NCT05191160 | The Soy Treatment Evaluation for Metabolic Health (STEM) Trial | Role of Soy for Metabolic Health: The Soy Treatment Evaluation for Metabolic Health (STEM) Trial | null | University of Toronto | UNKNOWN | INTERVENTIONAL | ["NA"] | 186 | University of Toronto | OTHER | ["United Soybean Board"] | ["Metabolic Syndrome", "Overweight and Obesity", "PreDiabetes", "Diabetes", "Healthy Obesity, Metabolically", "Overweight", "Obesity", "Dysglycemia", "Cardiovascular Diseases", "Heart Disease Risk Factors", "Hypertension", "Dyslipidemias"] | ["OTHER: Soy Milk", "OTHER: Cow's Milk", "OTHER: Sugar Sweetened Beverages"] | Strategies to reduce sugar-sweetened beverages (SSB) have become one of the leading public health targets to address the epidemics of obesity and diabetes. National food, nutrition, and health policies and programs have positioned low-fat milk as the preferred caloric replacement strategy for SSBs. This strategy derive... | ALL | 18 Years | 75 Years | true | 2021-11-02 | 2025-03-30 | 2024-10-30 | 2022-01-13 | 2024-04-18 | [{"facility": "Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital", "city": "Toronto", "state": "Ontario", "country": "Canada"}] | false | https://clinicaltrials.gov/study/NCT05191160 | 2026-05-14T17:51:05.781Z |
NCT06145360 | Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient | Effectivity of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes | null | SINA Health Education and Welfare Trust | COMPLETED | INTERVENTIONAL | ["PHASE4"] | 150 | SINA Health Education and Welfare Trust | OTHER | ["Horizon Pharmaceutical Pvt Ltd"] | ["Glucose Metabolism Disorders", "Diabetes Mellitus, Type 2", "Hypoglycemic Agents", "Empagliflozin"] | ["DRUG: Empagliflozin 10 MG", "DRUG: Insulin+Metformin+DPP4 inhibitor (DPP4I)"] | The primary aim of this study is to assess the impact of incorporating Empagliflozin, an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor, into the existing therapeutic regimen of Insulin+Metformin+Dipeptidyl peptidase 4 (DPP-4) inhibitors in poorly controlled type 2 diabetes mellitus (T2DM) patients. The study s... | ALL | 20 Years | 70 Years | false | 2023-12-01 | 2024-03-01 | 2024-03-01 | 2023-11-24 | 2024-04-08 | [{"facility": "SINA Shireen Jinnah colony", "city": "Karachi", "state": null, "country": "Pakistan"}] | false | https://clinicaltrials.gov/study/NCT06145360 | 2026-05-14T17:51:05.821Z |
NCT02806960 | A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes | A Single Center, Randomized, 4-Period Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Single or Repeated 3 mg Doses of Intranasally Administered Glucagon in Adults With Type 1 or Type 2 Diabetes | null | Eli Lilly and Company | TERMINATED | INTERVENTIONAL | ["PHASE1"] | 12 | Eli Lilly and Company | INDUSTRY | ["Locemia Solutions ULC"] | ["Diabetes Mellitus, Type 1", "Diabetes Mellitus, Type 2"] | ["DRUG: Nasal Glucagon"] | This study will investigate how the body processes nasal glucagon and the effect of nasal glucagon on the body. After an 8-hour overnight fast and 4 hours after the start of a low-carbohydrate breakfast, the study drug will be delivered into the participant's nostril(s) (intranasally) once or twice in each of four stud... | ALL | 18 Years | 70 Years | false | 2014-06 | 2014-08 | 2014-06 | 2016-06-21 | 2019-12-13 | [{"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Mount Royal", "state": "Quebec", "country": "Canada"}] | true | https://clinicaltrials.gov/study/NCT02806960 | 2026-05-14T17:51:05.866Z |
NCT06273124 | Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes | Open, Single Arm, Prospective, Multicenter Study of an Investigational Extended Wear Insulin Infusion Set During Home Use in People With Type 1 Diabetes | null | Tandem Diabetes Care, Inc. | COMPLETED | INTERVENTIONAL | ["NA"] | 260 | Tandem Diabetes Care, Inc. | INDUSTRY | ["Jaeb Center for Health Research"] | ["Type1diabetes"] | ["DEVICE: SteadiSet Extended Wear Infusion Set"] | The purpose of this study is to collect clinical data to support a 7-day wear of the Extended Wear Infusion Set (EWIS).
Participants will be asked to:
1. Wear the EWIS for up to 7 consecutive days for 12 consecutive wear periods
2. Perform blood glucose and ketone measurements if continuous glucose meter is ≥250mg/dL... | ALL | 18 Years | 80 Years | false | 2024-03-07 | 2024-12-11 | 2024-12-11 | 2024-02-22 | 2025-09-24 | [{"facility": "Hoag Memorial Hospital Presbyterian", "city": "Newport Beach", "state": "California", "country": "United States"}, {"facility": "Stanford University", "city": "Stanford", "state": "California", "country": "United States"}, {"facility": "Barbara Davis Center", "city": "Aurora", "state": "Colorado", "count... | true | https://clinicaltrials.gov/study/NCT06273124 | 2026-05-14T17:51:05.902Z |
NCT07139964 | High-Dose Vitamin D3 for Diabetic Foot Ulcer Healing: Randomized Controlled Trial | Effectiveness of High-Dose Vitamin D3 in Improving Diabetic Foot Ulcer Healing by Reducing the MMP-9 to TIMP-1 Ratio: Randomized Double-Blind Placebo-Controlled Trial | DFU | Universitas Sriwijaya | COMPLETED | INTERVENTIONAL | ["NA"] | 24 | Universitas Sriwijaya | OTHER | [] | ["Diabetic Foot Ulcer", "Vitamin D Deficiency", "Wound Healing Disorder"] | ["DIETARY_SUPPLEMENT: Vitamin D3", "OTHER: Placebo"] | This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the effectiveness of high-dose vitamin D3 supplementation in improving diabetic foot ulcer (DFU) healing. DFUs are common, serious complications of diabetes, often associated with delayed wound healing due to persistent inflammation, impa... | ALL | 18 Years | null | false | 2024-07-01 | 2025-07-31 | 2025-01-31 | 2025-08-24 | 2025-08-24 | [{"facility": "Dr. Mohammad Hoesin General Hospital", "city": "Palembang", "state": "South Sumatra", "country": "Indonesia"}] | false | https://clinicaltrials.gov/study/NCT07139964 | 2026-05-14T17:51:05.981Z |
NCT02776098 | Muscle Accrual and Function in Cystic Fibrosis-Impact of Glucose Intolerance | Muscle Accrual and Function in Cystic Fibrosis-Impact of Glucose Intolerance | null | Children's Hospital of Philadelphia | COMPLETED | OBSERVATIONAL | [] | 54 | Children's Hospital of Philadelphia | OTHER | ["National Institutes of Health (NIH)", "University of Pennsylvania", "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"] | ["Cystic Fibrosis"] | [] | This study will investigate the link between glucose abnormalities and elements critical to muscle function including mass, composition and energy metabolism. the primary goal of the study is to determine whether Cystic Fibrosis (CF) disease is associated with muscle dysfunction, especially in the presence of glucose i... | ALL | 12 Years | null | true | 2016-05 | 2024-03-04 | 2024-03-04 | 2016-05-18 | 2024-03-07 | [{"facility": "Children's Hospital of Philadelphia", "city": "Philadelphia", "state": "Pennsylvania", "country": "United States"}, {"facility": "University of Pennsylvania", "city": "Philadelphia", "state": "Pennsylvania", "country": "United States"}] | false | https://clinicaltrials.gov/study/NCT02776098 | 2026-05-14T17:51:06.023Z |
NCT02423798 | New Generation Enlite Accuracy Study | Accuracy and Performance Evaluation of the Medtronic New Generation Enlite Glucose Sensor in Conjunction With the Medtronic 640G System Components - in Clinic and at Home | null | Medtronic MiniMed, Inc. | COMPLETED | INTERVENTIONAL | ["NA"] | 24 | Medtronic MiniMed, Inc. | INDUSTRY | ["Profil Institut für Stoffwechselforschung GmbH"] | ["Diabetes"] | ["DEVICE: Glucose sensor (Enlite)"] | The trial will investigate the accuracy and performance of a new sensor for continuous glucose monitoring (CGM), the (new generation) Enlite, CE-marked in 2013, in conjunction with the new Medtronic 640G system components.
To evaluate the accuracy and performance of the new generation Enlite sensor. This is a postmark... | ALL | 18 Years | 74 Years | false | 2015-04 | 2015-09 | 2015-09 | 2015-04-22 | 2018-01-17 | [] | true | https://clinicaltrials.gov/study/NCT02423798 | 2026-05-14T17:51:06.079Z |
NCT02589314 | Effect of Periodontal Therapy in the Systemic Status of Individuals With Chronic Periodontitis and Diabetes Type 2 | Effect of Mechanical Periodontal Therapy in the Microbiological, Immunocellular and Immunoglobulin Profiles and in the Dosage of Pro and Anti-inflammatory Cytokines From Peripheral Blood and Saliva of Subjects With Chronic Periodontitis and Diabetes Type 2 | null | University of Brasilia | TERMINATED | OBSERVATIONAL | [] | 90 | University of Brasilia | OTHER | ["Catholic University of Brasília", "Brasilia University Hospital"] | ["Chronic Periodontitis", "Diabetes Type 2"] | ["DEVICE: Mechanical periodontal therapy", "PROCEDURE: nonsurgical periodontal therapy"] | This study will evaluate if periodontal mechanical treatment is capable to alter immunological and genetical parameters related to systemic health in patients with chronic periodontitis ant diabetes type 2. | ALL | 30 Years | 65 Years | true | 2015-11 | 2020-08 | 2019-09 | 2015-10-28 | 2020-08-24 | [{"facility": "Priscilla Farias Naiff", "city": "Brasília", "state": "Federal District", "country": "Brazil"}] | false | https://clinicaltrials.gov/study/NCT02589314 | 2026-05-14T17:51:06.094Z |
NCT00993304 | A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 Diabetics | A Trial to Assess the Effect of Liraglutide on Postprandial Triglyceride Levels in Subjects With Type 2 Diabetes | null | Novo Nordisk A/S | COMPLETED | INTERVENTIONAL | ["PHASE1"] | 20 | Novo Nordisk A/S | INDUSTRY | [] | ["Diabetes", "Diabetes Mellitus, Type 2"] | ["DRUG: liraglutide", "DRUG: placebo"] | This trial is conducted in Europe. The aim of this trial is to investigate whether a new compound, liraglutide, reduces the level of lipids (fat), including cholesterol, in the blood of type 2 diabetics, following a meal with high fat content. | ALL | 18 Years | null | false | 2009-10 | 2010-12 | 2010-12 | 2009-10-12 | 2017-01-26 | [{"facility": "Novo Nordisk Investigational Site", "city": "Aarhus C", "state": null, "country": "Denmark"}] | false | https://clinicaltrials.gov/study/NCT00993304 | 2026-05-14T17:51:06.125Z |
NCT00312104 | Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes | Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes. | null | Novo Nordisk A/S | COMPLETED | INTERVENTIONAL | ["PHASE3"] | 325 | Novo Nordisk A/S | INDUSTRY | [] | ["Diabetes", "Diabetes Mellitus, Type 1"] | ["DRUG: insulin detemir", "DRUG: insulin glargine", "DRUG: insulin aspart"] | The trial is conducted in Europe and Africa. The aim of the trial is to compare the use of insulin detemir twice daily combined with mealtime insulin aspart against that of insulin glargine once daily combined with mealtime insulin aspart. The trial involves patients with Type 1 Diabetes. | ALL | 18 Years | null | false | 2002-04 | 2003-03 | 2003-03 | 2006-04-07 | 2017-01-27 | [{"facility": "Novo Nordisk Investigational Site", "city": "Graz", "state": null, "country": "Austria"}, {"facility": "Novo Nordisk Investigational Site", "city": "Vienna", "state": null, "country": "Austria"}, {"facility": "Novo Nordisk Investigational Site", "city": "Vienna", "state": null, "country": "Austria"}, {"f... | false | https://clinicaltrials.gov/study/NCT00312104 | 2026-05-14T17:51:06.174Z |
NCT01075347 | Topical Autologous Serum Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries | Clinical Study: Topical Autologous Serum Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries | null | National Taiwan University Hospital | COMPLETED | INTERVENTIONAL | ["PHASE1"] | 165 | National Taiwan University Hospital | OTHER | [] | ["Corneal Epithelial Defect", "Diabetic Retinopathy", "Penetrating Keratoplasty"] | ["OTHER: autologous serum", "OTHER: Non-autologous serum"] | Ophthalmology ,cornea Autologous serum has long been known to be effective to promote corneal epithelial wound healing in a variety of ocular surface disorders. However, its effectiveness for corneal epithelial defects due to pars plana vitrectomy (PPV) for diabetic retinopathy and penetrating keratoplasty has seldom b... | ALL | 20 Years | 70 Years | true | 2007-03 | 2008-03 | 2008-03 | 2010-02-25 | 2010-09-14 | [{"facility": "National Taiwan University Hospital, department of Ophthalmology", "city": "Taipei", "state": "Taiwan", "country": "Taiwan"}] | true | https://clinicaltrials.gov/study/NCT01075347 | 2026-05-14T17:51:06.191Z |
NCT05874726 | Biological Sample Repository for Gastrointestinal Disorders | Biological Sample Repository for Gastrointestinal Disorders | null | Brigham and Women's Hospital | ACTIVE_NOT_RECRUITING | OBSERVATIONAL | [] | 500 | Pichamol Jirapinyo, MD, MPH | OTHER | ["Tufts University", "Boston Children's Hospital", "Mayo Clinic"] | ["Obesity", "Obesity, Morbid", "Obesity, Primary", "Gastro-Intestinal Disorder", "Overweight and Obesity", "Overweight", "Overweight or Obesity", "Diabetes Type 2", "Diabetes Mellitus", "Diabetes Mellitus, Type 2", "Hypertension", "Hyperlipidemias", "Sleep Apnea", "GERD", "Gastroesophageal Reflux", "Musculoskeletal Pai... | ["DIAGNOSTIC_TEST: Blood Collection", "DIAGNOSTIC_TEST: Urine Collection", "DIAGNOSTIC_TEST: Tissue Sample Collection"] | The goal of this observational study has the purpose of collecting biological samples from obese patients undergoing evaluation for weight loss by means of medical or endoscopic therapies; and of post bariatric surgery patients presenting with short- and long-term surgical complications. The aim is to enhance the overa... | ALL | 18 Years | null | false | 2023-07-19 | 2029-04 | 2028-07 | 2023-05-25 | 2025-12-02 | [{"facility": "Brigham and Women's Hospital", "city": "Boston", "state": "Massachusetts", "country": "United States"}] | false | https://clinicaltrials.gov/study/NCT05874726 | 2026-05-14T17:51:06.235Z |
NCT00741026 | A Crossover Study of the Acute Effects of Olanzapine in Healthy Volunteers | A Double-blind, Placebo-controlled, Crossover Study Examining the Acute Effects of Olanzapine on Plasma Leptin, Glucose Tolerance and Free Fatty Acids in Healthy Volunteers | null | Milton S. Hershey Medical Center | COMPLETED | INTERVENTIONAL | ["NA"] | 15 | Milton S. Hershey Medical Center | OTHER | ["American Medical Association"] | ["Insulin Resistance", "Diabetes Mellitus"] | ["DRUG: Olanzapine 10 mg po qhs for 3 days", "DRUG: Placebo"] | The purpose of this clinical research study is to examine the acute hormonal and metabolic effects of the drug olanzapine, as well as appetite effects, in healthy volunteers. The hypotheses to be tested are that: (1) Olanzapine rapidly attenuates plasma leptin and (2) rapidly alters glucose tolerance in healthy volunte... | ALL | 18 Years | 30 Years | true | 2008-08 | 2011-05 | 2010-12 | 2008-08-25 | 2014-07-14 | [{"facility": "Penn State College of Medicine, Penn State Milton S. Hershey Medical Center", "city": "Hershey", "state": "Pennsylvania", "country": "United States"}] | true | https://clinicaltrials.gov/study/NCT00741026 | 2026-05-14T17:51:06.252Z |
NCT04532385 | Effect of Green Tea Extract on Lipids in Patients With Type 2 Diabetes | Effect of a 12-week Administration of Green Tea Extract on Lipids in Patients With Type 2 Diabetes | HDL | Centro Universitario de Ciencias de la Salud, Mexico | COMPLETED | INTERVENTIONAL | ["NA"] | 20 | Centro Universitario de Ciencias de la Salud, Mexico | OTHER | [] | ["Diabetes Mellitus, Type 2", "Dyslipidemias", "Arterial Stiffness"] | ["DIETARY_SUPPLEMENT: Green tea extract", "DIETARY_SUPPLEMENT: Placebo"] | The main objectives of this study were to evaluate the effect of a 12-week supplementation with GTE (400 mg every 12 hours) on serum lipids, arterial stiffness and inflammatory cytokines in patients with T2DM. | ALL | 40 Years | 65 Years | false | 2018-06-12 | 2019-01-14 | 2019-01-14 | 2020-08-31 | 2020-08-31 | [{"facility": "Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara", "city": "Guadalajara", "state": "Jalisco", "country": "Mexico"}] | false | https://clinicaltrials.gov/study/NCT04532385 | 2026-05-14T17:51:06.273Z |
NCT00108615 | Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance | Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance | null | VA Office of Research and Development | COMPLETED | INTERVENTIONAL | ["PHASE4"] | 48 | US Department of Veterans Affairs | FED | [] | ["Glucose Metabolism Disorders", "Diabetes"] | ["DRUG: Metformin", "DRUG: Pioglitazone", "DRUG: Metformin", "DRUG: Pioglitazone", "RADIATION: CT scans", "PROCEDURE: Oral glucose tolerance test"] | Subjects with impaired glucose tolerance will be randomized to receive pioglitazone or metformin for 10 weeks. Measurements of insulin sensitivity, body composition, glucose tolerance, and muscle lipid accumulation will be performed. Adipose tissue and muscle biopsies are performed. The goal of the study is to determin... | ALL | 35 Years | 65 Years | true | 2004-01 | 2007-12 | 2007-04 | 2005-04-18 | 2008-04-25 | [{"facility": "Central Arkansas Veterans HCS", "city": "Little Rock", "state": "Arkansas", "country": "United States"}] | false | https://clinicaltrials.gov/study/NCT00108615 | 2026-05-14T17:51:06.318Z |
NCT05232708 | A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide | A Study to Demonstrate Bioequivalence Between Semaglutide Formulation for the DV3396 Pen-injector and the Formulation for the PDS290 Semaglutide Pen-injector | null | Novo Nordisk A/S | COMPLETED | INTERVENTIONAL | ["PHASE1"] | 18 | Novo Nordisk A/S | INDUSTRY | [] | ["Healthy Volunteers (Diabetes Mellitus, Type 2)"] | ["DRUG: Semaglutide B, 1.34 mg/mL", "DRUG: Semaglutide D, 1.0 mg/mL", "DRUG: Semaglutide D, 1.0 mg/mL", "DRUG: Semaglutide B, 1.34 mg/mL"] | In this trial, two approved solutions of the medicine semaglutide will be compared in healthy volunteers. The purpose of this trial is to see if semaglutide B and semaglutide D solutions are comparable with regards to moving into, through and out of the body when given in two separate injections. Participants will rece... | ALL | 20 Years | 55 Years | true | 2022-01-19 | 2022-08-30 | 2022-08-30 | 2022-02-10 | 2024-01-26 | [{"facility": "Parexel CPRU, Level 7", "city": "Harrow", "state": "Middlesex", "country": "United Kingdom"}] | false | https://clinicaltrials.gov/study/NCT05232708 | 2026-05-14T17:51:06.348Z |
NCT00641407 | Bedtime Insulins and Oral Antihyperglycemic Drugs in Type 2 Diabetes | Bedtime Insulin Glargine or Bedtime Neutral Protamine Lispro Combined With Sulfonylurea and Metformin in Type 2 Diabetes. A Randomized, Controlled Trial | null | University of Campania Luigi Vanvitelli | COMPLETED | INTERVENTIONAL | ["PHASE4"] | 100 | University of Campania Luigi Vanvitelli | OTHER | [] | ["Type 2 Diabetes Mellitus", "Hypoglycemia"] | ["DRUG: NPL insulin", "DRUG: Insulin glargine"] | The maintenance of nearly normal glycemic levels reduces the risk of diabetic complications, but is difficult to achieve, despite the administration of escalating doses of oral antidiabetic drugs, such as metformin, sulfonylureas, and thiazolidinediones. Most patients eventually require insulin which usually is added w... | ALL | 30 Years | 70 Years | false | 2007-01 | 2008-03 | 2007-12 | 2008-03-24 | 2008-03-31 | [{"facility": "Department of Geriatrics and Metabolic Disease", "city": "Naples", "state": null, "country": "Italy"}] | false | https://clinicaltrials.gov/study/NCT00641407 | 2026-05-14T17:51:06.386Z |
NCT04082000 | Phase 2a Study Examining the Safety and Efficacy of BOL-DP-o-04 for Treating Diabetic Neuropathy | A Phase 2a Study Examining the Safety and Efficacy of BOL-DP-o-04 Sublingual Drops for Treating Diabetic Neuropathy | null | Breath of Life International Pharma Ltd | TERMINATED | INTERVENTIONAL | ["PHASE1", "PHASE2"] | 2 | Breath of Life International Pharma Ltd | INDUSTRY | [] | ["Diabetic Neuropathy"] | ["DRUG: BOL-DP-o-04", "DRUG: Placebo"] | This is a randomized, double-blind, placebo-controlled Phase 2a Study Examining the Safety and Efficacy of BOL-DP-o-04 for Treating Diabetic Neuropathy | ALL | 18 Years | 80 Years | false | 2019-04-15 | 2020-11-04 | 2020-11-04 | 2019-09-09 | 2021-03-24 | [{"facility": "Wolfson Medical Center", "city": "Holon", "state": null, "country": "Israel"}] | false | https://clinicaltrials.gov/study/NCT04082000 | 2026-05-14T17:51:06.429Z |
NCT07515807 | Qatar Cardiometabolic Retrospective Cohort-Analysis Using Artificial Intelligence | Qatar Cardiometabolic Retrospective Cohort-Analysis Using Artificial Intelligence | QCRC-AI | Weill Cornell Medical College in Qatar | NOT_YET_RECRUITING | OBSERVATIONAL | [] | 10,000 | Weill Cornell Medical College in Qatar | OTHER | ["Hamad Medical Corporation"] | ["Cardio Vascular Disease", "Acute Coronary Syndromes (ACS)", "Type 2 Diabetes", "Pre Diabetes", "Artifical Intelligence"] | [] | Cardiovascular disease is the leading cause of death worldwide, and individuals with diabetes or other cardiometabolic conditions are at increased risk of adverse cardiovascular outcomes. Although advances in prevention and treatment have reduced cardiovascular events globally, cardiometabolic disease continues to repr... | ALL | 18 Years | null | false | 2026-07-16 | 2030-07-16 | 2030-07-16 | 2026-04-07 | 2026-04-21 | [{"facility": "Hamad Medical Corporation", "city": "Doha", "state": null, "country": "Qatar"}] | false | https://clinicaltrials.gov/study/NCT07515807 | 2026-05-14T17:51:06.447Z |
NCT01847092 | A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria | An Exploratory Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Design Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZD1722 in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria | null | Ardelyx | COMPLETED | INTERVENTIONAL | ["PHASE2"] | 154 | Ardelyx | INDUSTRY | ["AstraZeneca"] | ["Chronic Kidney Disease", "Type 2 Diabetes Mellitus"] | ["DRUG: AZD1722", "DRUG: Placebo"] | The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing albuminuria in patients with Chronic Kidney Disease with Type 2 Diabetes. | ALL | 18 Years | 80 Years | false | 2013-05 | 2015-04 | 2015-03 | 2013-05-06 | 2020-05-27 | [{"facility": "Creekside Endocrine Associates PC", "city": "Denver", "state": "Colorado", "country": "United States"}] | true | https://clinicaltrials.gov/study/NCT01847092 | 2026-05-14T17:51:06.482Z |
NCT00958711 | The Mechanism of Action of the Unite Biomatrix in Diabetic Foot Ulcer | The Mechanism of Action of the Unite Biomatrix in Diabetic Foot Ulcer | null | Baxter Healthcare Corporation | TERMINATED | INTERVENTIONAL | ["NA"] | 90 | Baxter Healthcare Corporation | INDUSTRY | ["Synovis Surgical Innovations"] | ["Diabetic Foot Ulcers"] | ["DEVICE: Unite Biomatrix", "OTHER: Saline and Gauze"] | The purpose of this study is to assess the mechanism of action of the Unite Biomatrix and compare its performance with the standard of care, saline moistened gauze, for the treatment of diabetic foot ulcers. | ALL | 18 Years | null | false | 2009-01 | 2012-05 | 2012-05 | 2009-08-13 | 2019-12-18 | [{"facility": "University of California - San Diego", "city": "San Diego", "state": "California", "country": "United States"}, {"facility": "University of Miami, Miller School of Medicine", "city": "Miami", "state": "Florida", "country": "United States"}, {"facility": "Aiyan Diabetes Center", "city": "Evans", "state": ... | true | https://clinicaltrials.gov/study/NCT00958711 | 2026-05-14T17:51:06.515Z |
NCT00198471 | Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment | An Open-label Assessment of Intravitreous Injections of Vitrase (Hyaluronidase for Injection) for Inducing Posterior Vitreous Detachment in Subjects With Moderate to Severe Non-proliferative Diabetic Retinopathy | null | Bausch & Lomb Incorporated | COMPLETED | INTERVENTIONAL | ["PHASE2"] | 10 | Bausch & Lomb Incorporated | INDUSTRY | [] | ["Vitreous Detachment", "Diabetic Retinopathy"] | ["DRUG: Vitrase"] | The purpose of this study is to assess the efficacy of intravitreous injections of Vitrase to induce posterior vitreous detachment(PVD) in subjects with moderate to severe non-proliferative diabetic retinopathy. | ALL | 50 Years | null | false | 2005-07 | 2006-11 | 2006-11 | 2005-09-20 | 2013-03-15 | [{"facility": "Edgar L. Thomas, MD", "city": "Beverly Hills", "state": "California", "country": "United States"}, {"facility": "Ronni Lieberman, MD", "city": "New York", "state": "New York", "country": "United States"}, {"facility": "Valley Retina Institute, PA", "city": "McAllen", "state": "Texas", "country": "United ... | false | https://clinicaltrials.gov/study/NCT00198471 | 2026-05-14T17:51:06.551Z |
NCT03248271 | Effects of Insulin on Hypotension and Sarcopenia | Effects of Insulin on Hypotension and Sarcopenia | null | University of British Columbia | WITHDRAWN | OBSERVATIONAL | [] | 0 | Kenneth Madden | OTHER | [] | ["Diabetes", "Sarcopenia", "Hypotension, Orthostatic"] | ["DRUG: Insulin Lispro"] | In this study investigator's aim to determine the impact of insulin therapy on hypotension and sarcopenia | ALL | 65 Years | null | null | 2017-10-01 | 2023-01-10 | 2023-01-10 | 2017-08-14 | 2023-01-12 | [{"facility": "University of British Columbia - Gerontology Research Lab", "city": "Vancouver", "state": "British Columbia", "country": "Canada"}] | false | https://clinicaltrials.gov/study/NCT03248271 | 2026-05-14T17:51:06.623Z |
NCT01705899 | Islet Allotransplantation in Type 1 Diabetes | Islet Allotransplantation in Type 1 Diabetes | null | Ohio State University | SUSPENDED | INTERVENTIONAL | ["PHASE1"] | 20 | Ohio State University | OTHER | [] | ["Type 1 Diabetes"] | ["DRUG: Human Pancreatic Islets"] | Islet transplantation can provide physiologic insulin replacement to patients with type 1 diabetes without the complications associated with whole pancreas transplantation. The purpose of this study is to achieve insulin-independence in patients with type 1 diabetes, thereby eliminating the need for exogenous insulin i... | ALL | 18 Years | 65 Years | false | 2006-11 | 2033-10 | 2033-10 | 2012-10-12 | 2025-01-16 | [{"facility": "The Ohio State University Medical Center", "city": "Columbus", "state": "Ohio", "country": "United States"}] | false | https://clinicaltrials.gov/study/NCT01705899 | 2026-05-14T17:51:06.662Z |
NCT06103799 | Application of Information-Motivation-Behavioral Model-based Continuity of Care on the Peri-implantitis Recovery in Diabetic Implant Overdenture Patients | Application of Information-Motivation-Behavioral Model-based Continuity of Care on the Peri-implantitis Recovery in Diabetic Implant Overdenture Patients: A Randomised Controlled Trial | null | The Dental Hospital of Zhejiang University School of Medicine | COMPLETED | INTERVENTIONAL | ["NA"] | 32 | The Dental Hospital of Zhejiang University School of Medicine | OTHER | [] | ["Bone Resorption", "Diabetes"] | ["BEHAVIORAL: IMB model-based continuity of care"] | The investigators recruited 32 diabetic IOD patients with a total of 110 problematic implants who had completed the treatment for peri-implantitis between January 2021 and March 2023 as research subjects. The patients were randomly assigned to the control group or the experimental group using the random number table. T... | ALL | null | null | false | 2023-01-01 | 2023-09-30 | 2023-09-20 | 2023-10-27 | 2023-10-27 | [{"facility": "The Stomatologic Hospital, School of Medicine, Zhejiang University", "city": "Hangzhou", "state": "Zhejiang", "country": "China"}] | false | https://clinicaltrials.gov/study/NCT06103799 | 2026-05-14T17:51:06.702Z |
NCT06474598 | An Adaptive Design Study of MTX228 | A Open Label, Parallel Group Phase IIA, Adaptive Design Study of MTX228 in Adult Subjects With Type 1 Diabetes and Preserved β-Cell Function | null | University of Alberta | RECRUITING | INTERVENTIONAL | ["PHASE2"] | 24 | University of Alberta | OTHER | [] | ["Type 1 Diabetes Mellitus"] | ["DRUG: MTX228", "DEVICE: DEXCOM G6"] | MTX228 has been identified as a medication that might allow the re-growth of insulin producing beta cells in people with Type 1 Diabetes. Promoting the re-growth of lost beta cells would be beneficial to people with Type 1 Diabetes because it would allow them to take less insulin by injection and would improve their ov... | ALL | 18 Years | 65 Years | false | 2024-11-14 | 2027-12 | 2026-10 | 2024-06-25 | 2026-04-13 | [{"facility": "University of Alberta", "city": "Edmonton", "state": "Alberta", "country": "Canada"}] | false | https://clinicaltrials.gov/study/NCT06474598 | 2026-05-14T17:51:06.885Z |
NCT05316298 | Diabetic Foot Osteomyelitis Treatment Using Gentamicin-loaded Calcium Sulfate-hydroxyapatite Biocomposite | Gentamicin-loaded Calcium Sulfate-hydroxyaPatite Biocomposite to tREat Diabetic Foot Ulcers Complicated by oSteomyElitis: a pRospectiVE Cohort Study | PRESERVE | University Medical Center Groningen | UNKNOWN | OBSERVATIONAL | [] | 182 | University Medical Center Groningen | OTHER | ["Ziekenhuisgroep Twente", "Slingeland Hospital", "Franciscus Gasthuis", "UMC Utrecht", "Rijnstate Hospital", "Jeroen Bosch Ziekenhuis", "Reinier de Graaf Groep", "St. Antonius Hospital", "St Jansdal Hospital", "Maasstad Hospital"] | ["Diabetic Foot Ulcer", "Osteomyelitis", "Diabetes Mellitus"] | [] | The amputation risk is high when diabetic foot ulcers, complicated by osteomyelitis, fail to heal after non-surgical standard-of-care treatment. A new treatment regimen has been developed recently and has been proven feasible. This treatment regimen consists of surgical debridement, followed by bone void filling with g... | ALL | 18 Years | null | false | 2022-12-01 | 2025-01-01 | 2025-01-01 | 2022-04-07 | 2022-11-16 | [{"facility": "Jeroen Bosch Hospital", "city": "'s-Hertogenbosch", "state": null, "country": "Netherlands"}, {"facility": "Hospitalgroup Twente", "city": "Almelo", "state": null, "country": "Netherlands"}, {"facility": "Rijnstate Hospital", "city": "Arnhem", "state": null, "country": "Netherlands"}, {"facility": "Reini... | false | https://clinicaltrials.gov/study/NCT05316298 | 2026-05-14T17:51:06.927Z |
NCT07387393 | To Test the Effectiveness and Implementation Approach of a 3-month PILI Pasifika Program Lifestyle Program With Components of Social Determinants of Health Activities in Real-world Settings (Clinical and Non-clinical Settings) Across 3 Years | Peau o le Vasa: Accelerating the Currents of Health Advances for Pasifika People | null | University of Hawaii | NOT_YET_RECRUITING | INTERVENTIONAL | ["NA"] | 400 | University of Hawaii | OTHER | ["National Association of Pasifika Organizations", "Papa Ola Lōkahi", "National Heart, Lung, and Blood Institute (NHLBI)"] | ["Cardiometabolic Conditions", "Hypertension (HTN)", "Dyslipidemia", "Pre-diabetes", "Type 2 Diabetes Mellitus (T2DM)", "Overweight (BMI > 25)", "Weight Loss Trial"] | ["BEHAVIORAL: PILI (Partnership for Improving Lifestyle Intervention) Pasifika Program"] | In this study, the investigators are conducting a Type 3 hybrid effectiveness-implementation trial to evaluate the implementation of the Community Health Workers (CHW)-delivered PILI Pasifika Program (PPP) across 3 regions, the U.S. Affiliated Pacific Islands (USAPI), the continental U.S., and Hawai'i, among 400 Native... | ALL | 18 Years | null | false | 2026-05-01 | 2028-10-31 | 2028-09-15 | 2026-02-04 | 2026-04-22 | [{"facility": "National Association of Pasifika Organizations", "city": "Fayetteville", "state": "Arkansas", "country": "United States"}, {"facility": "Papa Ola Lokahi", "city": "Honolulu", "state": "Hawaii", "country": "United States"}] | false | https://clinicaltrials.gov/study/NCT07387393 | 2026-05-14T17:51:06.994Z |
NCT00408993 | Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China | Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China | null | Eli Lilly and Company | COMPLETED | INTERVENTIONAL | ["PHASE3"] | 215 | Eli Lilly and Company | INDUSTRY | ["Boehringer Ingelheim"] | ["Diabetic Neuropathies"] | ["DRUG: Duloxetine Hydrochloride", "DRUG: Placebo"] | To determine if duloxetine 60mg up to 120mg daily can work in treating pain from Diabetic Neuropathy. | ALL | 18 Years | null | false | 2006-12 | 2008-02 | 2008-02 | 2006-12-08 | 2011-07-26 | [{"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Beijing", "state": null, "country": "China"}, {"facility": "... | true | https://clinicaltrials.gov/study/NCT00408993 | 2026-05-14T17:51:07.038Z |
NCT01002521 | Wound Healing In Diabetes (WHy) Study | Molecular and Genetic Analysis of Disturbed Wound Healing in Barbadians With Diabetic Foot Ulcers | WHy | The University of The West Indies | UNKNOWN | OBSERVATIONAL | [] | 605 | The University of The West Indies | OTHER | ["Chronic Disease Research Centre", "Barbados Diabetes Foundation"] | ["Impaired Wound Healing", "Diabetes Mellitus"] | [] | This observational study aims to identify risk factors and molecular mechanisms of impaired wound healing, to guide better foot care in the diabetic population. | ALL | null | null | false | 2009-12 | 2012-06 | 2011-06 | 2009-10-27 | 2009-10-27 | [{"facility": "Chronic Disease Research Centre", "city": "Bridgetown", "state": "Saint Michael", "country": "Barbados"}] | false | https://clinicaltrials.gov/study/NCT01002521 | 2026-05-14T17:51:07.083Z |
NCT00001733 | Screening for Studies on Retinovascular Diseases | Screening Study for the Evaluation and Diagnosis of Potential Research Subjects With Retinovascular Diseases | null | National Institutes of Health Clinical Center (CC) | COMPLETED | OBSERVATIONAL | [] | 2,000 | National Eye Institute (NEI) | NIH | [] | ["Diabetic Retinopathy", "Macular Degeneration", "Pathologic Neovascularization", "Retinal Disease"] | [] | This screening protocol is designed to help recruit patients for National Eye Institute (NEI) studies of the retina, such as diabetic retinopathy and macular degeneration. Patients must meet the specific criteria of a research study, and this protocol serves as a first step for admitting patients to a retinal disease s... | ALL | 18 Years | null | true | 1998-03-06 | 2008-07-02 | null | 1999-11-04 | 2017-07-02 | [{"facility": "National Institutes of Health Clinical Center, 9000 Rockville Pike", "city": "Bethesda", "state": "Maryland", "country": "United States"}] | false | https://clinicaltrials.gov/study/NCT00001733 | 2026-05-14T17:51:07.102Z |
NCT07075133 | Chrono-restricted Diet and Physical Activity as a New Preventive Strategy for Sarcopenia in Postmenopausal Women With Obesity and Type 2 Diabetes | Chrono-restricted Diet and Physical Activity as a New Preventive Strategy for Sarcopenia in Postmenopausal Women With Obesity and Type 2 Diabetes | TIMEDIAB | University Hospital, Toulouse | NOT_YET_RECRUITING | INTERVENTIONAL | ["NA"] | 45 | University Hospital, Toulouse | OTHER | [] | ["Obesity", "Sarcopenia", "Post Menopause", "Type 2 Diabetes", "Circadian Clock"] | ["OTHER: Antidiabetic diet (control)", "OTHER: eTRE diet", "OTHER: Physical activity in the morning", "OTHER: Physical activity in the afternoon"] | The aim of TIMEDIAB is to demonstrate that early TRE (eTRE) combined to late (afternoon) exercise will outperform eTRE combined to morning exercise on muscle function as primary endpoint, and glucose homeostasis as secondary endpoint | ALL | 45 Years | 70 Years | true | 2025-07-15 | 2029-07-15 | 2029-07-15 | 2025-07-20 | 2025-07-20 | [{"facility": "Rangueil Hospital", "city": "Toulouse", "state": "France", "country": "France"}] | false | https://clinicaltrials.gov/study/NCT07075133 | 2026-05-14T17:51:07.140Z |
NCT04213547 | Sleep and Glycemic Control in Type 2 Diabetes Adolescents | Sleep Duration and Glycemic Control in Adolescents With Type 2 Diabetes Mellitus | null | Children's Hospital of Philadelphia | RECRUITING | INTERVENTIONAL | ["NA"] | 90 | Children's Hospital of Philadelphia | OTHER | ["National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"] | ["Type 2 Diabetes"] | ["BEHAVIORAL: Loss frame sleep extension intervention"] | The primary objective is to determine the cross-sectional relationship between sleep duration (as measured by 14 days of actigraphy) and glycemic control in an adolescent Type 2 Diabetes (T2DM) cohort (age 12-20y, n=67). A secondary objective is to determine if a loss-framed incentive for achieving sleep goals can incr... | ALL | 12 Years | 20 Years | false | 2020-09-16 | 2026-06-01 | 2026-06-01 | 2019-12-30 | 2026-04-03 | [{"facility": "Children's Hospital of Philadelphia", "city": "Philadelphia", "state": "Pennsylvania", "country": "United States"}] | false | https://clinicaltrials.gov/study/NCT04213547 | 2026-05-14T17:51:07.166Z |
NCT00534547 | Duodenal Exclusion for the Treatment of Type 2 Diabetes | Phase IV Study of Duodenal Exclusion for the Treatment of Type 2 Diabetes (T2DM) | null | Medtronic - MITG | WITHDRAWN | INTERVENTIONAL | ["NA"] | 0 | Medtronic - MITG | INDUSTRY | [] | ["Diabetes"] | ["PROCEDURE: Duodenal Exclusion"] | The purpose of this study is to investigate the role of an experimental surgery that may offer better short and long-term control of T2DM in select patients who have not achieved adequate blood sugar control with regular means. | ALL | 20 Years | 50 Years | false | null | null | null | 2007-09-26 | 2015-07-27 | [] | false | https://clinicaltrials.gov/study/NCT00534547 | 2026-05-14T17:51:07.241Z |
NCT07385547 | Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency | A Phase 1 Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of GL0034 | null | Sun Pharmaceutical Industries Limited | RECRUITING | INTERVENTIONAL | ["PHASE1"] | 40 | Sun Pharmaceutical Industries Limited | INDUSTRY | [] | ["Type II Diabetes Mellitus"] | ["DRUG: GL0034"] | This is an open-label, single-dose, Phase 1 clinical study designed to evaluate the effect of renal impairment on the pharmacokinetics (PK) of GL0034, a long-acting GLP-1 receptor agonist. Approximately 40 adult participants will be enrolled across four groups: normal renal function, moderate renal impairment, severe r... | ALL | 18 Years | 80 Years | true | 2026-02-25 | 2026-09-27 | 2026-09 | 2026-02-04 | 2026-03-13 | [{"facility": "Syneos Miami", "city": "Miami", "state": "Florida", "country": "United States"}, {"facility": "Panax Clinical Research", "city": "Miami Lakes", "state": "Florida", "country": "United States"}, {"facility": "Orlando Clinical Research Center (OCRC)", "city": "Orlando", "state": "Florida", "country": "Unite... | false | https://clinicaltrials.gov/study/NCT07385547 | 2026-05-14T17:51:07.279Z |
NCT00806858 | Observational Study of NovoPen® 4 on Treatment Satisfaction of Insulin Therapy in Type 1 or Type 2 Subjects With Diabetes Mellitus | NovoPen®4 Clinical Experience Programme: A Multicentre, Observational Study of NovoPen®4 on Treatment Satisfaction of Insulin Therapy in Type 1 or Type 2 Subjects With Diabetes Mellitus | null | Novo Nordisk A/S | COMPLETED | OBSERVATIONAL | [] | 526 | Novo Nordisk A/S | INDUSTRY | [] | ["Diabetes", "Diabetes Mellitus, Type 1", "Diabetes Mellitus, Type 2", "Delivery Systems"] | ["DEVICE: NovoPen® 4"] | This study is conducted in Asia. The aim of this observational study is to evaluate subjects' treatment satisfaction and to evaluate subjects' preference of pen device and the incidence of clinical technical complains while using NovoPen® 4 under normal clinical practice conditions. | ALL | null | null | false | 2008-11 | 2009-07 | 2009-07 | 2008-12-11 | 2016-11-23 | [{"facility": "Novo Nordisk Investigational Site", "city": "Beijing", "state": "Beijing Municipality", "country": "China"}] | false | https://clinicaltrials.gov/study/NCT00806858 | 2026-05-14T17:51:07.298Z |
NCT01943357 | Improving Self Management Skills of Older Adults With Diabetes | Improving the Self Management Skills of Older Adults With Diabetes | null | Stanford University | COMPLETED | INTERVENTIONAL | ["NA"] | 1,000 | Stanford University | OTHER | ["HealthCore, Inc."] | ["Type 2 Diabetes", "Diabetes"] | ["BEHAVIORAL: Diabetes Self Management Program"] | The study will help determine if the Better Choices Better Health Diabetes program (community-based or online, also known as the Diabetes Self-Management Program) improves the hbA1C of people with Type-II diabetes. The investigators will also examine 1) symptoms (fatigue, sleep, low blood sugar symptoms, depression, sh... | ALL | 18 Years | null | false | 2013-09 | 2017-02 | 2016-03 | 2013-09-16 | 2017-04-25 | [{"facility": "Stanford University School of Medicine", "city": "Stanford", "state": "California", "country": "United States"}] | false | https://clinicaltrials.gov/study/NCT01943357 | 2026-05-14T17:51:07.318Z |
NCT00278057 | STUDY OF GLUCOSE IN DIALYSIS WATER WITH REGARD TO BLOOD PRESSURE AND QUALITY OF LIFE | PHASE 4 STUDY OT THE EFFECT OF GLUCOSE ADDED TO THE DIALYSIS FLUID ON BLOOD PRESSURE, BLOOD GLUCOSE AND QUALITY OF LIFE IN HEMODIALYSIS PATIENTS. | null | Regional Hospital Holstebro | COMPLETED | INTERVENTIONAL | ["PHASE4"] | 55 | Regional Hospital Holstebro | OTHER | [] | ["Hemodialysis"] | ["DRUG: dialysisis with and without glucose in the dialysis"] | We wanted to test the hypotheses that blood pressure level was lower, that the variability of blood pressure and blood glucose was reduced, and that quality of life was improved when glucose was added to the dialysis fluid. | ALL | 18 Years | null | false | 2003-05 | 2003-05 | null | 2006-01-18 | 2006-01-18 | [{"facility": "Department of Medicine, Holstebro Hospital", "city": "Holstebro", "state": null, "country": "Denmark"}] | false | https://clinicaltrials.gov/study/NCT00278057 | 2026-05-14T17:51:07.334Z |
NCT02356757 | Preventing Amputations by Tailored Risk-based Intervention to Optimize Therapy | Preventing Amputations by Tailored Risk-based Intervention to Optimize Therapy | PATRIOT | VA Office of Research and Development | COMPLETED | INTERVENTIONAL | ["NA"] | 406 | VA Office of Research and Development | FED | [] | ["Diabetes", "Foot Ulcer"] | ["BEHAVIORAL: Personalized Behavioral Intervention", "BEHAVIORAL: Current Best Practice"] | The PATRIOT study will evaluate a risk-based personalized behavioral intervention to improve foot self-care, self-monitoring, and modifiable risks for amputation such as blood glucose, blood pressure and cholesterol in order to prevent diabetic foot ulcers in patients at higher than normal risk for amputation. This nov... | ALL | 21 Years | null | false | 2015-08-24 | 2021-09-30 | 2021-06-30 | 2015-02-05 | 2021-10-22 | [{"facility": "Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY", "city": "New York", "state": "New York", "country": "United States"}] | false | https://clinicaltrials.gov/study/NCT02356757 | 2026-05-14T17:51:07.367Z |
NCT01194830 | Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study | A Phase IIIb, 24-week, Randomised, Placebo-controlled, Double-blinded, Efficacy and Safety Study of Linagliptin (BI 1356) in Black/African American Patients With Type 2 Diabetes With a MTT Sub-study | null | Boehringer Ingelheim | COMPLETED | INTERVENTIONAL | ["PHASE3"] | 234 | Boehringer Ingelheim | INDUSTRY | ["Eli Lilly and Company"] | ["Diabetes Mellitus, Type 2"] | ["DRUG: Linagliptin", "DRUG: Placebo"] | Study of linagliptin vs. placebo in Black/African American patients with T2DM with a MTT sub-study | ALL | 18 Years | 80 Years | false | 2010-09 | 2011-10 | 2011-10 | 2010-09-03 | 2014-01-29 | [{"facility": "1218.75.059 Boehringer Ingelheim Investigational Site", "city": "Birmingham", "state": "Alabama", "country": "United States"}, {"facility": "1218.75.054 Boehringer Ingelheim Investigational Site", "city": "Huntsville", "state": "Alabama", "country": "United States"}, {"facility": "1218.75.035 Boehringer ... | true | https://clinicaltrials.gov/study/NCT01194830 | 2026-05-14T17:51:07.385Z |
NCT05205928 | Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care | Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care: a Double-blind, Cross-over, Randomized Controlled Trial | SEMA-AP | McGill University Health Centre/Research Institute of the McGill University Health Centre | COMPLETED | INTERVENTIONAL | ["PHASE2", "PHASE3"] | 28 | McGill University Health Centre/Research Institute of the McGill University Health Centre | OTHER | [] | ["Type 1 Diabetes", "Diabetes Mellitus, Type 1"] | ["DRUG: Outpatient therapy: 11 weeks of drug therapy with usual treatment + 4 weeks of closed-loop therapy"] | A closed-loop insulin system, also referred to as the "artificial pancreas" (AP), is made up of an insulin pump, a continuous glucose monitor, and an application communicating between the two to adjust insulin administration based on glucose control. This is meant for the treatment of type 1 diabetes. The McGill Artifi... | ALL | 18 Years | null | false | 2022-10-02 | 2024-06-30 | 2024-04-15 | 2022-01-25 | 2025-01-22 | [{"facility": "Research Institute of the McGill University Health Centre", "city": "Montreal", "state": "Quebec", "country": "Canada"}] | false | https://clinicaltrials.gov/study/NCT05205928 | 2026-05-14T17:51:07.411Z |
NCT07560800 | Effect of Beetroot Juice on Cardiovascular and Autonomic Responses to Exercise in Adults With Type 2 Diabetes | Effect of Beetroot Juice on Cardiovascular and Autonomic Responses During and After Exercise in Adults With Type 2 Diabetes | DiaBEET | Oxford Brookes University | NOT_YET_RECRUITING | INTERVENTIONAL | ["NA"] | 20 | Oxford Brookes University | OTHER | [] | ["Type 2 Diabetes Mellitus", "Hypertension", "Autonomic Nervous System Diseases"] | ["DIETARY_SUPPLEMENT: Beetroot juice", "DIETARY_SUPPLEMENT: Nitrate-depleted Beetroot Juice Placebo"] | This study will investigate whether a single dose of beetroot juice can improve cardiovascular responses and recovery after exercise in adults with Type 2 Diabetes.
Type 2 Diabetes is associated with higher blood pressure, impaired blood vessel function, and reduced autonomic control of the heart, all of which increas... | ALL | 40 Years | 65 Years | false | 2026-04-02 | 2026-07-31 | 2026-07-31 | 2026-05-01 | 2026-05-01 | [{"facility": "Clinical Physiology Laboratory, Oxford Brookes University", "city": "Oxford", "state": "Oxfordshire", "country": "United Kingdom"}] | false | https://clinicaltrials.gov/study/NCT07560800 | 2026-05-14T17:51:07.438Z |
NCT05683392 | Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers With Type 1 Diabetes | Control-IQ 2.0 Feasibility Study #2: Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers With Type 1 Diabetes | null | Tandem Diabetes Care, Inc. | COMPLETED | INTERVENTIONAL | ["NA"] | 72 | Tandem Diabetes Care, Inc. | INDUSTRY | [] | ["Type 1 Diabetes"] | ["DEVICE: t:slim X2 insulin pump with Control-IQ technology 2.0"] | The goal of this clinical trial is to assess safety of and explore glycemic outcomes with Control-IQ technology 2.0 in adults, children and preschoolers with type 1 diabetes. | ALL | 2 Years | 80 Years | false | 2023-02-01 | 2023-12-13 | 2023-12-13 | 2023-01-13 | 2024-12-20 | [{"facility": "Barbara Davis Center (Pediatric Clinic)", "city": "Aurora", "state": "Colorado", "country": "United States"}, {"facility": "Barbara Davis Center", "city": "Aurora", "state": "Colorado", "country": "United States"}, {"facility": "Joslin Diabetes Center", "city": "Boston", "state": "Massachusetts", "countr... | true | https://clinicaltrials.gov/study/NCT05683392 | 2026-05-14T17:51:07.494Z |
NCT04860336 | Glycemic Observation and Metabolic Outcomes in Mothers and Offspring | Glycemic Observation and Metabolic Outcomes in Mothers and Offspring / Glycemic Profile of Pregnancy Consortium | GO MOMs | Northwestern University | COMPLETED | OBSERVATIONAL | [] | 2,179 | Northwestern University | OTHER | ["National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "Yale University", "Women and Infants Hospital of Rhode Island", "University of Pittsburgh", "Massachusetts General Hospital", "Tufts Medical Center", "Columbia University", "Kaiser Permanente"] | ["Gestational Diabetes", "Pregnancy Related"] | ["OTHER: Observational"] | The overarching goal of Glycemic Observation and Metabolic Outcomes in Mothers and Offspring (GO MOMs) is to perform a comprehensive, longitudinal description of maternal glycemia over the course of pregnancy and to evaluate how glucose levels throughout pregnancy relate to traditional third trimester gestational diabe... | FEMALE | 18 Years | null | false | 2021-04-01 | 2025-07-18 | 2025-06-09 | 2021-04-26 | 2026-04-16 | [{"facility": "Yale University", "city": "New Haven", "state": "Connecticut", "country": "United States"}, {"facility": "Kaiser Permanente - Hawaii", "city": "Honolulu", "state": "Hawaii", "country": "United States"}, {"facility": "Northwestern University", "city": "Chicago", "state": "Illinois", "country": "United Sta... | false | https://clinicaltrials.gov/study/NCT04860336 | 2026-05-14T17:51:07.524Z |
NCT01880736 | A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily (OD) Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes | A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes | null | Novo Nordisk A/S | COMPLETED | INTERVENTIONAL | ["PHASE3"] | 458 | Novo Nordisk A/S | INDUSTRY | [] | ["Diabetes", "Diabetes Mellitus, Type 2"] | ["DRUG: insulin degludec", "DRUG: insulin degludec", "DRUG: insulin degludec"] | This trial is conducted in Asia. The aim of the trial is to investigate the efficacy and safety of flexible versus fixed dosing and simple versus stepwise titration with OD insulin degludec in inadequately treated subjects with type 2 diabetes. | ALL | 20 Years | null | false | 2013-06 | 2014-04 | 2014-04 | 2013-06-19 | 2017-02-10 | [{"facility": "Novo Nordisk Investigational Site", "city": "Chuo-ku, Tokyo", "state": null, "country": "Japan"}, {"facility": "Novo Nordisk Investigational Site", "city": "Chuo-ku, Tokyo", "state": null, "country": "Japan"}, {"facility": "Novo Nordisk Investigational Site", "city": "Fukui-shi, Fukui", "state": null, "c... | true | https://clinicaltrials.gov/study/NCT01880736 | 2026-05-14T17:51:07.542Z |
NCT03942471 | Mindfulness for Adolescents With Type 1 Diabetes | The Effects of Learning Mindfulness Based Stress Reduction on Psychosocial Variables and HbA1c in Adolescents With Type 1 Diabetes | null | Duquesne University | COMPLETED | INTERVENTIONAL | ["NA"] | 65 | Duquesne University | OTHER | [] | ["Type 1 Diabetes Mellitus"] | ["BEHAVIORAL: Mindfulness Based Stress Reduction"] | Adolescents with Type 1 Diabetes will be invited to the Mindfulness study. They will be randomly assigned to a Control or Active Group. The Active Group will learn Mindfulness Based Stress Reduction (MBSR) through an online website designed to teach the basic principles of MBSR in six week-long modules. They will be me... | ALL | 12 Years | 19 Years | false | 2015-10-14 | 2019-01-05 | 2018-10-01 | 2019-05-08 | 2019-05-08 | [] | false | https://clinicaltrials.gov/study/NCT03942471 | 2026-05-14T17:51:07.596Z |
NCT04917471 | Effect of Nitrate on Red Blood Cell Function in Type 2 Diabetes | The Effect of Dietary Nitrate Supplementation on Red Blood Cell Function in Patients with Type 2 Diabetes | null | Karolinska Institutet | RECRUITING | INTERVENTIONAL | ["NA"] | 20 | Karolinska Institutet | OTHER | [] | ["Type 2 Diabetes"] | ["DIETARY_SUPPLEMENT: Beet root juice", "DIETARY_SUPPLEMENT: Placebo juice"] | To investigate the effect of nitrate supplementation on red blood cell function in patients with type 2 diabetes. | ALL | 18 Years | null | false | 2021-06-01 | 2025-12-31 | 2025-12-30 | 2021-06-08 | 2024-10-09 | [{"facility": "Karolinska Institutet, Karolinska University Hospital", "city": "Stockholm", "state": null, "country": "Sweden"}] | false | https://clinicaltrials.gov/study/NCT04917471 | 2026-05-14T17:51:07.616Z |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.